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Overview 
This thesis explores the utility of established performance validity tests 
(PVTs) for assessing non-neurological aspects of test-taking behaviour in clinical 
populations. Part one is a systematic literature review examining the classification 
accuracy of a range of PVTs in dementia populations. Consideration is given to the 
impact of dementia severity and diagnosis on PVT specificity. Issues surrounding the 
use of cut-off scores on these measures are discussed. Part two is an empirical study 
exploring the base rate of failure on commonly-used PVTs in a sample of NHS 
acquired brain injury patients. The relationship between PVT failure and overall 
performance on cognitive testing is also assessed. Part three is a critical appraisal of 
the thesis which reflects on the broader clinical and conceptual challenges inherent in 
the field of performance validity testing as a whole.  
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Part 1: Literature review 
The assessment of performance validity in dementia: a systematic review 
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Abstract 
Aims: Performance validity tests (PVTs) are included in neuropsychological test 
batteries to assess if results offer a reliable estimate of the individual’s cognitive 
ability. Research exploring how individuals with dementia perform on these 
measures is limited. This review aims to synthesise the literature on the use of PVTs 
in dementia, with particular focus on the identified specificity of these measures 
across different severities and diagnoses. 
Method: Systematic electronic searches were conducted on PsychINFO and 
MEDLINE databases to identify studies utilising validated PVTs with dementia 
samples. Methodological quality of the studies was assessed using the ‘QualSyst’ 
critical appraisal tool. PVT specificity data was subsequently extracted and pooled 
across studies to assess classification accuracy.  
Results: Twenty-four studies were identified which investigated a total of 31 PVTs. 
Pooled specificity was examined for 11 PVTs. Only Vocabulary Minus Digit Span, 
Trail-Making Test Ratio and Coin in the Hand tests achieved adequate specificities 
of over 90%. PVTs with dementia profile algorithms, however, showed consistently 
higher classification accuracy. Results pointed to the potential influence of dementia 
severity and diagnosis on PVT failure.  
Conclusions: The majority of PVTs used in UK clinical practice demonstrated 
inadequate specificity when used with clinical dementia populations. There is further 
evidence to suggest that PVTs may be sensitive to cognitive impairment. Adjusting 
cut-off scores has been found to improve specificity, but the concomitant reduction 
in sensitivity brings their ability to identify invalid performance into question. The 
clinical implications of these findings are discussed.  
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Introduction 
‘Dementia’ is a broad term encompassing a number of progressive 
neurological conditions characterised by deterioration in multiple cognitive domains 
including memory, executive functions and language (Salmon & Bondi, 2009). 
Neuropsychological assessments are a performance-based method of assessing 
cognitive functioning frequently completed as part of diagnostic evaluations (Salmon 
& Bondi, 2009; MKhann et al., 2011; Sperling et al., 2011). They can provide 
important evidence to support the differential diagnosis of dementias with diverse 
cognitive profiles and to delineate between dementia and alternative causes of 
memory impairment (Harvey, 2012). They can also help clinicians identify strengths 
and weaknesses to inform clinical recommendations for treatment in addition to 
tracking longitudinal changes in cognition (Walter, Morris, Swier-Vosnos, & Pliskin, 
2014). Given that neuropsychological assessment is a primary source of information 
in dementia diagnosis and management, it is of particular importance that the 
contributing test data offer a reliable estimate of a person’s ability. This review will 
focus on the assessment of invalid performance and the application of conventional 
assessment tools to individuals with suspected or confirmed dementia diagnoses.  
The concept of examinee ‘effort’  
Neuropsychological test data are prone to a range of biases which must be 
considered potential invalidating factors (Rudman, Oyebode, Jones, & Bentham, 
2011). Test performance can be impaired for a number of reasons apart from 
neurological disease (Vickery, Berry, Inman, Harris, & Orey, 2001). One key factor 
is whether the examinee provided the clinician with a full and accurate impression of 
their symptoms and applied themselves adequately – or exerted maximum ‘effort’ - 
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during psychometric testing. It has been recognised that clinicians’ ability to make ad 
hoc informal judgements of examinee ‘effort’ is poor (Faust, Hart, Guilmetter, & 
Arkes, 1988), indeed, it is recognised that the true extent of someone’s motivation to 
apply themselves to testing is essentially unknowable (Suesse et al., 2015). 
Nonetheless, clinicians administering neuropsychological assessments have a 
responsibility to make determinations about test validity (Bush et al., 2005) and, as 
such, need to consider how such evaluations are made. In line with this, a 2009 
document published by the British Psychological Society (BPS; McMillan et al., 
2009), highlighted that addressing the issue of data quality is good practice in 
neuropsychological assessment. These guidelines emphasise that clinical assessments 
should routinely include valid and reliable indices sensitive to ‘distortions of 
motivation’, frequently referred to as ‘effort tests’. In turn, this has led to a surge in 
the development of novel measures to meet this need. 
The term ‘effort testing’ is ubiquitous, however, it is part of a nomenclature 
derived from medicolegal literature which frequently conflates ‘poor effort’ with 
malingering – the intentional production of exaggerated complaints, usually in the 
presence of external incentive (Slick, Sherman, & Iverson, 1999). This is misleading, 
and demonstrates a misconception about the properties of such tests, which can only 
observe and measure behaviour, not intent (Boone et al., 2002a). Using such 
terminology risks communicating over-simplistic categorisations: ‘good effort’ or 
‘poor effort’ clients may be seen to have ‘credible’ or ‘non-credible’ performance 
which could, in turn, lead to potentially unhelpful interpretations regarding the 
source of such behaviour (for example that distortion in performance is intentional). 
To mitigate this issue, Bush et al. (2005) utilise the phrase ‘investment in performing 
at capacity levels’ rather than ‘effort’, which highlights a broader construction than 
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malingering alone, as there may be myriad reasons for reduced performance such as 
fatigue, side effects of medication or depressed mood (Bortnick, Horner, & 
Bachman, 2013; Walter et al., 2014), factors which are highly relevant in clinical 
settings. To reflect this position, this review will henceforth use the term 
‘performance validity’ and associated ‘performance validity tests (PVTs)’ as per 
Larrabee (2012), who distinguishes the validity of ability task performance (as 
captured by the measures discussed below) from the accuracy of symptomatic 
complaint (as portrayed on symptom self-report measures, which are not examined in 
this review). 
The measurement of performance validity 
PVTs appear subjectively difficult to the examinee but are in fact measures 
designed to have a very low test ceiling. They purport to be insensitive to actual 
cognitive dysfunction, meaning that the majority of people applying themselves to 
the testing should achieve scores at or near the ceiling regardless of underlying 
neurological impairment (Tombaugh, 1997). Scores below chance on these measures 
are considered indicative of potential malingering when occurring in the presence of 
an external incentive (Slick et al., 1999). Anyone performing below ceiling and 
‘failing’ the measures, however, would also raise questions about additional 
influences on performance and, concomitantly, the validity of the remaining 
neuropsychological data gathered in the assessment.  
There are a range of PVTs available. Some are designed specifically for this 
purpose, such as the Test of Memory Malingering (TOMM; Tombaugh, 1996) or the 
Word Memory Test (WMT; Green, Allen, & Astner, 1996). These are referred to as 
‘standalone’ PVTs and frequently take the form of recognition memory measures 
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using a ‘forced choice’ paradigm. There are also conventional psychometric tests 
which have established supplementary utility as PVTs. For example, Reliable Digit 
Span (RDS) can be computed from the Weschler Adult Intelligence Scale (WAIS) 
Digit Span subtest (Greiffenstein, Baker, & Gola, 1994), with the rationale that 
performance well below the ‘normal’ range on both forwards and backwards Digit 
Span tasks is relatively unusual in bona fide patients with documented brain damage 
(Iverson & Tulsky, 2003). These ‘embedded’ measures have the additional benefits 
of being less vulnerable to coaching and not adding to assessment times (McMillan 
et al., 2009). It has been recommended that clinicians take a ‘multi-method, multi-
test’ approach to assessing performance validity, using a number of measures testing 
different cognitive domains (Larrabee, 2014).  
Sensitivity and specificity: the psychometric foundations of performance validity 
testing 
Test validity concerns the ability of a test to detect the presence or absence of 
a particular characteristic in the examinee. The validity of PVTs is evaluated using 
the psychometric concepts of sensitivity and specificity which indicate the likelihood 
of obtaining a true or a false positive respectively. The balance between the two is 
related to the cut-off score on the test: with PVTs,  more stringent cut-offs are more 
likely to correctly identify those not performing at capacity levels (better sensitivity) 
but the resulting pool of individuals will likely include individuals who are 
performing at capacity levels (reduced specificity; Iverson & Brooks, 2011, p. 931). 
In clinical settings, the focus should be on maximising specificity over sensitivity to 
minimise the risk of false positive errors, as there are possible clinical, financial, 
occupational and emotional consequences for the patient associated with being 
labelled as having ‘suspect effort’ or ‘invalid performance’ (Greve & Bianchini, 
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2004). As such, within the PVT literature the trend has been to set a threshold for 
adequate test specificity at 90 per cent or greater (Vickery et al., 2001; Larrabee, 
2008). 
Measuring performance validity in dementia 
The prolific body of literature demonstrating the efficacy of both standalone 
and embedded PVTs stems primarily from North American forensic and medicolegal 
contexts, where the examinees most frequently present with acquired brain injury 
and there are issues of potential secondary gain (for example, financial compensation 
or insurance claims). Little is known about their utility in clinical populations with 
confirmed or suspected diagnoses of dementia (Bortnick et al., 2013). Although 
many PVTs have been validated with cognitively impaired samples, these frequently 
exclude individuals with dementia, making it difficult to ascertain if reported cut-offs 
are appropriate for use in this population (Dean, Victor, Boone, Philpott, & Hess, 
2009). A number of reasons have been proposed for this, for example the belief that 
older adults with dementia would rarely be incentivised to perform poorly (Kiewel, 
Wisdom, Bradshaw, Pastorek, & Strutt, 2012), though this perspective fails to 
recognise that a) there are myriad reasons (both explicit and implicit) why someone 
might be motivated to obtain a particular diagnostic status and b) invalid 
performance does not necessarily represent intentional underperformance. Although 
it is theoretically easy for most neurological patients to meet the task demands of 
PVTs it is unclear if this is the case in dementia, particularly in the more advanced 
stages. It may therefore represent a serious diagnostic error to conclude overall 
invalid performance based on PVT failure in this population. For these reasons, it is 
important to analyse the classification accuracy of PVTs in dementia populations 
across the spectrum of severity (Henry, Merten, Wolf, & Harth, 2010). Given the 
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growing incidence of dementia and the need for cognitive testing to support early 
diagnosis (Illife, Manthorpe, & Eden, 2003), in addition to professional guidelines 
highlighting the importance of performance validity testing for comprehensive 
neuropsychological assessment, this gap in the literature presents a challenge for 
clinicians.   
The aim of the present literature review 
To date, no systematic review has been published focusing specifically on 
performance validity measurement in dementia. A 2009 study by Dean and 
colleagues included an overview of the existing literature which indicated some 
promise for Digit Span indicators (Vocabulary Minus Digit Span, Iverson & Tulsky, 
2003 and four-digit forward span time score, Babikian, Boone, Lu, & Arnold, 2006), 
the Medical Symptom Validity Test (MSVT; Green, 2004) and the Trail Making Test 
(TMT; Iverson, Lange, Green & Franzen, 2002). However, they emphasised the 
paucity of evidence in dementia samples. Since 2009, the PVT literature has 
burgeoned, and there is increased recognition that it is of clinical significance to 
identify which PVTs can be usefully employed in patients with possible dementia. 
The overall aim of the current review is therefore to synthesise current information 
regarding the performance of dementia patients on commonly-used PVTs. The key 
questions that this review seeks to address are as follows: 
1) Which PVTs offer the greatest degree of classification accuracy (specificity) 
in a dementia population? 
2) Should clinicians be using adjusted cut-offs to achieve adequate specificity on 
these PVTs in dementia populations?  
3) Is PVT classification accuracy impacted by dementia severity or type? 
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Method 
Search strategy 
Initial searches were conducted on the electronic databases PsychInfo and 
Medline to identify relevant studies published up to August 2017. Three umbrella 
search term categories were identified (see Table 1), with additional search terms 
identified from key words in existing research studies. Terms were initially entered 
separately and then combined. Results were limited to human adult participants (over 
18 years of age), written in the English language and peer-reviewed journals. It is 
recognised that utilising only published data may introduce a publication bias, 
however, this increased the likelihood that only high-quality data were included. 
Reference lists of included articles were also hand-searched to identify additional 
studies not picked up by the electronic search. This included a consultation of 
relevant review papers in this area (e.g. Dean et al, 2009).  
Inclusion and exclusion criteria 
The inclusion and exclusion criteria were guided by previous review papers 
in the PVT literature (e.g. Vickery et al., 2001; Sollman & Berry, 2011) to maximise 
the quality and specificity of the studies included. A flow diagram is provided (see 
Figure 1) to indicate where studies were eliminated from the final literature pool. 
Measures used: Studies were selected if they investigated at least one established 
embedded or stand-alone PVT (see McMillian et al., 2009, pp 6-7 and Appendix 3 
for information on commonly used PVTs). Note that measures are not described in 
full in this review to protect the fidelity of these instruments. 
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Table 1: Electronic search strategy  
Search term category Terms applied Combined with 
Performance validity test Performance validity 
test* 
 
 Symptom validity test*            OR 
 Effort test*  
 Validity indicator*  
   
Dementia Dementia                         AND 
 Alzheimer?s disease  
 Vascular dementia  
 Fronto?temporal 
dementia / FTD 
            OR 
 Memory disorder*  
 Mild cognitive 
impairment / MCI 
                                          AND               
   
   
Symptom validity Symptom validity  
 Performance validity             
 Malingering            OR            
 Suboptimal effort  
 Response bias  
   
 
Notes: *Denotes truncation, looks for variants of words such as test, tests, testing 
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 Figure 1: Flow diagram illustrating the inclusion of studies in the review       
Electronic database 
search 
(n = 668)
Removal of duplicates
(n = 617)
Results screened
(n = 617)
Hand search of 
references and review 
papers
(n = 4)
Excluded
(n = 531)
Excluded (n = 62)
No performance 
validity test used (n=1)
No dementia sample / 
mixed clinical sample 
(n=48)
Case study / small case 
series (n=9)
No objective dementia 
diagnosis (n=2)
Inclusion of previously 
used sample (n=1)
Not experimental 
design (n=1)
Studies included in qualitative synthesis
(n = 24)
Full text screened
(n = 86)
Studies included in classification accuracy analysis
(n = 11)
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Study design: Both retrospective and prospective studies were included. Single case 
designs or case series were excluded. Some studies were found to use the same 
sample over a number of different studies: these data were included where the studies 
contributed unique information (for example, data on different measures), but not 
where the same outcomes were reported.  
Participants: Selected studies were required to have a clinical dementia sample. The 
definition of ‘dementia’ was kept purposefully broad to capture the maximum 
number of studies. Alzheimer’s disease (AD), vascular dementia (VD) and 
frontotemporal dementia (FTD) samples were included. Mild cognitive impairment 
(MCI) samples were not included, as evidence is mixed as to whether this constitutes 
a separate clinical entity to dementia or a symptomatic prodromal phase (Petersen et 
al., 1999; Dubois et al., 2010). Mixed samples where separate data were not provided 
for dementia alone were also excluded (for example, Barker, Horner, & Bachman, 
2010; Novitski, Karantzoulis, & Randolph, 2012). Studies investigating other 
progressive conditions such as Huntington’s disease, Parkinson’s disease and 
multiple sclerosis were excluded. 
Sample size: Sample sizes of less than 20 are generally considered ‘small’ in 
quantitative studies (Pallant, 2013; p 216).  Small sample sizes are particularly 
problematic when investigating classification accuracy for measures with binary 
outcomes, as each individual represents a larger proportion of the sample (for 
example, one false positive out of a sample of 20 will represent a 5% reduction in 
specificity). As such, a cut-off of 20 participants was set to compromise between 
maximising study numbers and preventing the inclusion of data which may be 
skewed due to small samples.  
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Data collection and extraction 
All studies identified were initially screened by title for relevance. Studies 
referencing performance validity in dementia populations were subject to detailed 
abstract screening. Full text articles were acquired for studies deemed appropriate, 
and these were subsequently analysed to ascertain if the above criteria were met. 
Quality appraisal  
The identified references were screened for quality using the ‘QualSyst’ 
critical appraisal tool (Kmet, Lee, & Cook, 2004), which enables the ‘systematic, 
reproducible and quantitative’ assessment of studies with disparate methodologies. 
Like all quality appraisal tools, Qualsyst represents the authors’ subjective opinions 
of the elements that constitute study quality. It was also developed with a relatively 
small sample of test studies and includes limited investigation of inter-rater reliability 
(Kmet et al., 2004). However, in the absence of a ‘gold standard’ measure against 
which to compare studies (Katrak, Bialocerkowski, Massy-Westropp, Kumar, & 
Grimmer, 2004), it constitutes a useful means of supplementing the qualitative 
assessment of data quality.  
The QualSyst method employs a 14-item checklist to assess the internal 
validity of the study design and analysis. Studies are scored depending on the degree 
to which certain criteria are met: a score of two indicates that the criteria are fully 
met; one is partially met and zero indicates that the criteria are not met. Summary 
scores can be calculated for each study by summing the total score gained across the 
items and dividing by the total possible score. A cut-off point of 0.75 was chosen as 
a relatively conservative indicator of quality. Some checklist items (Criteria 5, 6 and 
7) were excluded as they were not relevant to any of the studies in the shortlist, 
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primarily because the studies were not interventional and the nature of the population 
meant that investigator blinding was not possible.  
Evaluation of PVT classification accuracy 
The majority of studies identified only allowed for the calculation of 
specificity, as using samples of ‘bona fide’ dementia patients theoretically means that 
there should be no ‘invalid’ performance to identify and thus no sensitivity values to 
compute. Where studies have identified subsamples of ‘suspect effort’ patients or 
used simulator samples, it follows that sensitivity could also be calculated. This 
analysis focused on specificity, as all studies provided this information and, 
clinically, this is the more informative value. 
To evaluate the measures, specificity values were extracted from the studies 
or calculated based on the percentage of dementia patients appropriately passing the 
PVT. This requires an assumption that bona fide patients failing the test represent 
false positives, a limitation of the approach which is addressed in further detail in the 
discussion. Specificity data was then pooled across studies, collapsing where 
necessary across severity and diagnosis within study dementia samples. This method 
of assessing PVT classification accuracy across studies has been reported in previous 
meta-analyses (Vickery et al., 2001; Sollman & Berry, 2011; Schroeder, Twumasi-
Ankrah, Baade, & Marshall, 2012). Using this method enables all studies to be 
included in the calculations, but it is recognised that it does not control for between-
study heterogeneity and correlations (Schroeder et al., 2012). To account for these 
limitations, 95% confidence intervals were included. As specificity is a proportion, 
confidence intervals were calculated using the standard methods for proportions 
(Altman & Bland, 1994). Pooled specificity was only calculated where there were 
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two or more studies using the same measure and cut-off, which limited the amount of 
data available for the analysis.  
 
Results 
Overview 
The review yielded 24 studies meeting the inclusion criteria. Thirteen studies 
were retrospective, using data from clinic or research archives. The remaining studies 
were prospective in that participants were enrolled in the research as part of their 
routine clinical assessments. No studies published prior to 1997 met the inclusion 
criteria. Twenty-two reported independent findings and two reported data from the 
same sample examining different PVTs (Howe, Anderson, Kaufman, Sachs, & 
Loring, 2007; Howe & Loring, 2009).  
Study characteristics 
Aims: The majority of studies cited the overall aim of investigating the performance 
or ‘clinical utility’ of a particular PVT (or multiple PVTs) in a dementia population. 
One study (Green et al., 2011) additionally aimed to cross-validate the MSVT and 
WMT cut-offs in a non-English speaking population.  
Measures: Across the 24 studies, 31 PVTs were investigated: these are identified in 
Table 2. For a brief overview of the format and content of key measures the reader is 
referred to Table 1 and Appendix 3 in McMillan et al. (2009; pp. 6-7 and 21-24). The 
majority of measures were established tests of performance validity such as the 
TOMM (Tombaugh, 1997) whereas others were novel measures derived from 
existing validated tests (such as the Repeatable Battery for the Assessment of 
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Neuropsychological Status Effort Index [RBANS EI]; Silverberg, Wertheimer, & 
Fichtenberg, 2007). A combination of embedded (such as RDS; Greiffenstein et al., 
1994) and standalone (such as WMT; Green et al., 1996) measures were utilised. The 
selected studies represented the majority of measures identified as ‘commonly used’ 
in UK clinical neuropsychological practice (McMillan et al., 2009; McCarter et al., 
2009).  
Samples: All studies included a dementia sample though clinical characteristics 
varied. The majority used ‘mixed dementia types’ (n = 19), within which AD was the 
most common presentation. The remainder (n = 5) specified the dementia subtype 
(most commonly AD). Comparison groups varied and included different severities of 
dementia (n = 9), different dementia subtypes (n = 6) and comparisons between 
dementia and different forms of acquired brain damage, most commonly traumatic 
brain injury (n = 7). A number of studies utilised age-matched normal controls (n = 
7). One study included a large control group taken from the standardisation sample 
of the WAIS-III (Iverson & Tulsky, 2003) but did not include the clinical 
characteristics of this sample. Six studies included a comparison group of individuals 
categorised as ‘poor’ or ‘suspect’ effort (a ‘known groups’ sample), or simulator 
sample.  
Settings and design: Studies were published between 1997 and 2016. The majority 
were American or Canadian studies, with two from the UK (Singhal, Green, Ashaye, 
& Gill, 2009; Rudman et al., 2011) and one from Germany (Merten, Bossnick, & 
Schmand, 2007). Traditionally, there is a North American bias in the PVT literature, 
as PVTs have been utilised there for longer and are a key element in medicolegal  
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Table 2: Summary of studies included in the review with key findings 
Authors 
(year) 
Total 
dementia 
sample 
size 
Dementia 
sample 
type 
Incentive 
to feign 
PVTs 
assessed  
Data 
included in 
classification 
analysis 
Compares 
dementia 
group with 
KG/simulators 
Compares 
dementia 
severities 
Compares 
dementia 
subtypes 
Key findings Quality 
appraisal 
overall 
score 
 
Dean et al 
(2009) 
214 Mixed 
dementia 
types 
No Digit Span ACSS 
RDS 
Timed Digit Span 
Vocabulary 
Minus Digit Span 
Dot counting test 
TOMM T2 
Warrington RMT 
(words) 
RFIT 
WMS-III logical 
memory RMI 
Finger tapping 
b-test 
Rey word 
recognition 
equation 
RAVLT equation 
Rey-O equation 
Rey-O/RAVLT 
equation 
ü û ü ü Majority of tests demonstrated high FP error rates 
 
Most specificities fell in the range of 
30%-70% 
 
Lower MMSE scores associated with 
increased test failure 
 
Adjusting cut-offs to provide ≥90% 
specificity rendered several measures 
inappropriate for use in dementia 
0.86 
Walter et al 
(2014) 
31 Mixed 
dementia 
types of 
moderate-
severe 
severity 
No TOMM T2 
 ü û ü û 
Approximately 20% of moderate to 
severe dementia group failed TOMM T2 
 
No significant difference between 
TOMM T2 scores between control and 
MCI groups 
 
1.00 
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Authors 
(year) 
Total 
dementia 
sample 
size 
Dementia 
sample 
type 
Incentive 
to feign 
PVTs 
assessed  
Data 
included in 
classification 
analysis 
Compares 
dementia 
group with 
KG/simulators 
Compares 
dementia 
severities 
Compares 
dementia 
subtypes 
Key findings Quality 
appraisal 
overall 
score 
 
Bortnick et al 
(2013) 
128 Mixed 
dementia 
types 
Unlikely RBANS EI 
TMT 
RFIT 
(TOMM used as 
classification 
variable for effort 
groups) 
ü ü ü ü Majority of measures demonstrated unacceptably high FP rates in patients 
classified as having ‘adequate’ 
motivation 
 
Specificities ranged from of 0% for 
RFIT combination to 99% for TMT 
ratio. Sensitivity values ranged from 0% 
for TMT ratio to 100% for RFIT (recall 
and combination)  
 
Patients with milder forms of dementia 
(MMSE >25) at higher risk of 
misclassification 
 
0.86 
Teichner & 
Wagner (2004) 
21 Mixed 
dementia 
types 
Not 
reported 
TOMM T2 and 
retention 
 
ü û û û High misclassification rates for dementia sample - specificity 24% on 
TOMM T2 
 
Specificity 100% for cognitively intact 
sample and 92.7% for cognitively 
impaired group  
 
0.95 
Tombaugh 
(1997) 
37 
 
Mixed 
dementia 
types 
No TOMM T2 and 
retention ü û û û Classification accuracy of dementia group using TOMM T2 significantly 
lower than other groups: 92% versus 
>97% 
 
0.95 
Merten et al. 
(2007) 
20 AD Not 
reported 
ASTM 
WMT 
TOMM T2 and 
retention 
ü û û û Only 10% of Alzheimer’s patients passed ASTM and WMT. 70% passed 
TOMM T2  
 
All control participants passed all tests 
 
0.86 
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Authors 
(year) 
Total 
dementia 
sample 
size 
Dementia 
sample 
type 
Incentive 
to feign 
PVTs 
assessed  
Data 
included in 
classification 
analysis 
Compares 
dementia 
group with 
KG/simulators 
Compares 
dementia 
severities 
Compares 
dementia 
subtypes 
Key findings Quality 
appraisal 
overall 
score 
 
Rudman et al. 
(2011) 
42 Mixed 
dementia 
types 
Not 
reported 
MSVT 
NV-MSVT 
TOMM T2 and 
retention 
Dot counting test 
RFIT 
Coin in the hand 
ü û ü û Mild dementia group performed significantly better on all six measures 
that the moderate / severe group 
 
RFIT and TOMM were the most 
sensitive to severity of cognitive 
impairment 
 
Dot counting test (time) was the only 
measure that achieved 100% specificity 
 
No significant correlations between 
emotional functioning and measures of 
performance validity 
 
0.95 
Burton et al. 
(2015) 
145 Mixed 
dementia 
types 
No RBANS EI 
RBANS ES ü û ü ü RBANS EI: 48% of total sample scored below cut-off. Increased severity of 
dementia associated with increased 
likelihood of scoring below cut-off 
 
RBANS ES: 14% of total sample scored 
below cut-off. ES not highly associated 
with dementia severity however, non-
AD subsample had increased likelihood 
of scoring below cut-off 
 
0.86 
Dunham et al. 
(2014) 
46 Mixed 
dementia 
types 
(including n 
= 1 with  
MCI) 
No RBANS EI 
RBANS ES 
(MSVT used as 
grouping 
variable) 
ü ü û û RBANS ES demonstrated high specificity in dementia sample (81%), EI 
had low specificity (41%) 
 
Classification rates of ES relatively 
stable across different severities of 
cognitive impairment, EI rates declined 
as cognitive functioning decreased 
 
Comparable rates of sensitivity found 
for simulation sample 
 
0.91 
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Authors 
(year) 
Total 
dementia 
sample 
size 
Dementia 
sample 
type 
Incentive 
to feign 
PVTs 
assessed  
Data 
included in 
classification 
analysis 
Compares 
dementia 
group with 
KG/simulators 
Compares 
dementia 
severities 
Compares 
dementia 
subtypes 
Key findings Quality 
appraisal 
overall 
score 
 
Duff et al. 
(2011) 
126 AD Not 
reported 
RBANS EI ü û û û Base rates of failure on EI ranged from 3% in cognitively intact OA to 33% in 
AD 
 
Years of education was related to EI 
performance in nursing home residents, 
MCI patients and AD patient samples  
 
0.91 
Kiewel et al. 
(2012) 
142 AD  No Digit span ACSS 
RDS 
LDSF (1 trial) 
LDSF (2 trials) 
Vocab-digit span 
ü û ü û RDS demonstrated unacceptably high FP rates in moderate and severe AD 
(76% and 17% respectively) 
 
Classification accuracy overall 
decreased with increasing AD severity 
on all measures with exception of 
Vocab-Digit span (which was not tested 
in the severe group) 
 
1.00 
Greve et al. 
(2006) 
22 Diagnosed 
memory 
disorder – 
suspected 
AD, VD or 
both 
No TOMM T1, T2 
and retention ü ü û û Memory disorder patients performed more poorly than TBI patients 
(specificity T2 is 82%) 
 
All three trials detected known 
malingerers with TBI with a low FP 
error rate of approximately 5% 
 
0.86 
Iverson & 
Tulsky (2003) 
38 AD Not 
reported 
Digit span ACSS, 
LDSF, LDSB, 
Vocabulary-Digit 
Span ACSS 
ü û û û Digit span ACSS demonstrated specificity of 95% in AD 
 
Vocabulary-Digit Span ACSS 
demonstrated specificity of 97% 
 
0.91 
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Authors 
(year) 
Total 
dementia 
sample 
size 
Dementia 
sample 
type 
Incentive 
to feign 
PVTs 
assessed  
Data 
included in 
classification 
analysis 
Compares 
dementia 
group with 
KG/simulators 
Compares 
dementia 
severities 
Compares 
dementia 
subtypes 
Key findings Quality 
appraisal 
overall 
score 
 
Howe et al. 
(2007) 
31 ‘Early’ 
dementia  
(n = 13) 
‘Advanced’ 
dementia   
(n = 18) 
No MSVT  
MSVT dementia 
profile algorithm 
û û ü û Using established symptom validity indices (IR, DR, CNS) specificity for 
early dementia was approximately 61% 
and for advanced dementia 17% 
 
With application of the dementia profile 
algorithm, specificity for early dementia 
increased to 92% and advanced 
dementia to 89% 
 
0.95 
Green et al. 
(2011) 
65 Mixed 
dementia 
types 
Not 
reported 
WMT 
MSVT û û û û 
Specificity of WMT and MSVT was 
98.4% or higher in dementia patients 
with use of dementia profile analysis 
 
0.95 
Howe & 
Loring (2009) 
31* ‘Mild-
Moderate 
dementia’  
(n = 13) 
‘Severe 
dementia’  
(n = 18) 
 
No MSVT û û ü û With use of dementia profile, FP rate was 5.8% (36/52 patients in total sample 
correctly classified) 
 
0.95 
Boone et al. 
(2002) 
37 ‘Mild’ 
dementia  
(n = 16) 
‘Moderate’ 
dementia  
(n = 21) 
Not 
reported 
 
Dot Counting 
Test ü ü ü û Specificity in mild dementia = 75% and in moderate dementia = 33.4%  
 
Fairly robust in the context of mild 
dementia with relatively few incorrect 
identifications – provides advantages 
over memory-based PVTs 
 
0.95 
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Authors 
(year) 
Total 
dementia 
sample 
size 
Dementia 
sample 
type 
Incentive 
to feign 
PVTs 
assessed  
Data 
included in 
classification 
analysis 
Compares 
dementia 
group with 
KG/simulators 
Compares 
dementia 
severities 
Compares 
dementia 
subtypes 
Key findings Quality 
appraisal 
overall 
score 
 
Arnold et al. 
(2005) 
31 AD (n = 12) 
Non AD 
dementia  
(n = 18) 
Not 
reported 
Finger tapping 
test û ü û ü 
Men tapped faster than women across all 
groups, therefore groups divided by 
gender 
 
Dominant hand scores proved more 
sensitive to non-credible performance 
 
Across all groups, cut-off scores 
yielding highest sensitivity and 
specificity values were dominant hand ≤ 
28 for women and ≤ 35 for men 
 
Useful in discriminating performance 
validity in AD but less effective in non-
AD dementias due to motor component 
 
0.91 
Schroeder at 
al. (2012) 
45 Mixed 
dementia 
No Coin in the hand 
test ü û û ü 
11% of patients made 2 or more errors 
(89% specificity at this cut-off) 
 
No patient made > 4 errors 
 
73% obtained perfect scores 
0.86 
Henry et al. 
(2010) 
21 Mixed 
dementia 
No NV-MSVT û û û û 13/21 dementia patients failed ‘A’ criteria 
With addition of ‘B’ criteria none of the 
dementia patients were classified as 
having invalid performance  
 
0.95 
Loring et al. 
(2007) 
50 Mixed 
dementia 
types 
 
No VSVT û û û û At a cut off of <21 hard items, specificity was 62% 0.86 
Schroeder & 
Marshall 
(2010) 
22 Not 
specified 
Not 
reported 
Sentence 
repetition test û û û û Specificity 77% for cut-off score of 9 and 64% for cut-off score of 10 
 
0.86 
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Authors 
(year) 
Total 
dementia 
sample 
size 
Dementia 
sample 
type 
Incentive 
to feign 
PVTs 
assessed  
Data 
included in 
classification 
analysis 
Compares 
dementia 
group with 
KG/simulators 
Compares 
dementia 
severities 
Compares 
dementia 
subtypes 
Key findings Quality 
appraisal 
overall 
score 
 
Loring et al. 
(2016) 
178 ‘Early’ AD Not 
reported 
RDS 
AVLT logistic 
regression 
AVLT 
recognition 
ü û ü û RDS specificity at ≤7 was 66% and at ≤6 was 87% for ‘early’ AD 
 
AVLT indices yielded unacceptably  
high false-positive rates at a range of 
cut-offs 
 
Combining embedded PVT indicators 
lowered the false-positive rates 
 
0.86 
Zenisek et al. 
(2016) 
183 Mixed 
dementia 
types 
 
No RDS ü û û ü RDS specificity at ≤6 across dementia subtypes ranged from 73% - 83%. A 
criterion of ≤7 resulted in unacceptably 
low specificity. 
 
Those scoring below cut-offs performed 
worse on cognitive measures than those 
scoring above cut-offs.  
 
1.00 
Notes: KG = Known Groups; FP = false positive; AD = Alzheimer’s disease; VD = Vascular Dementia; DLB = Dementia with Lewy Bodies; FTD = Fronttemporal Dementia; MCI = Mild Cognitive Impairment; OA 
= Older Adults; TBI = Traumatic Brain Injury; LD = Learning Disability; CVA = Cerebrovascular Accident; NOS = Not Otherwise Specified; MS = Multiple Sclerosis 
 
Measures: Test of Memory Malingering (TOMM; Tombaugh, 1996); Digit Span Age Corrected Scaled Score (Digit Span ACSS; Babikian, Boone, Lu & Arnold, 2006); Reliable Digit Span (RDS; Greiffenstein et 
al., 1994); Timed Digit Span (Babikian et al., 2006); Vocabulary Minus Digit Span (Iverson & Tulsky, 2003); Dot Counting Test E-Score (Boone, Lu & Herzberg, 2002); Dot Counting Test (DCT; Lezak, 1995); 
Warrington Recognition Memory Test (Warrington RMT; Iverson & Franzen, 1994); Rey 15-item Test (RFIT; Free Recall Lezak, 1983, p619; Recognition Equation, Boone, Salazar, Lu, Warner-Chacon & Razani, 
2002); Weschler Memory Scale-III Logical Memory Rarely Missed Index (WMS-III RMI; Killgore & DellaPietra, 2000); Finger Tapping dominant hand (Arnold et al., 2005); b-Test E-score (Boone et al., 2002); 
Medical Symptom Validity Test (MSVT; Green, 2004); Non-Verbal Medical Symptom Validity Tests (NV-MSVT; Green, 2008); Victoria Symptom Validity Test (VSVT; Slick, Hopp & Strauss, 1997); Rey 
Auditory Verbal Learning Test Effort Equation (RAVLT; Boone, Lu & Wen, 2005); Rey-Osterreith Effort Equation (Rey-O; Lu, Boone, Cozolino & Mitchell, 2003); Rey-Osterreith /RAVLT discriminant function 
(Rey-O/RAVLT; Sherman, Boone, Lu & Razani, 2002); Rey word recognition equation (Nitch, Boone, Wen, Arnold & Alfano, 2006); Longest Digit Span Forwards (LDSF; Babikian et al., 2006); Longest Digit 
Span Backwards (LDSF; Iverson & Tulsky, 2003); Repeatable Battery for the Assessment of Neuropsychological Status Effort Index (RBANS EI; Silverberg, Wertheimer & Fichtenberg, 2007); Repeatable Battery 
for the Assessment of Neuropsychological Status Effort Scale (RBANS ES; Novitski, Steele, Karantzoulis & Randolph, 2012); The Amsterdam Short Term Memory Test (ASTM; Schagen, Schmand, de Sterke & 
Lindeboom 1997); The Word Memory Test (WMT; Green, Allen & Astner, 1996); Trail Making Test (TMT; Iverson, Lange, Green & Franzen, 2002); Sentence Repetition Test (SRT; Strauss, Sherman & Spreen, 
2006); The Coin in the Hand Test (Kapur, 1994); Auditory Verbal Learning Test (AVLT) logistic regression (Davis. Millis, & Axelrod, 2012); AVLT recognition (Binder, Villanueva, Howieson, & Moore, 1993) 
 
*Same sample as used in Howe et al. (2007)  
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assessments (Suesse et al., 2015). Most of the data was derived from clinical practice 
and all studies were cross-sectional and between groups in design.  
Appraisal of identified studies: An overview of the quality appraisal for each study is 
shown in Table 3. Scores ranged between 0.86 and 1.0 and no study was excluded on 
the basis of the appraisal. Overall, studies scored highly on sufficiently describing 
the study aims, use of appropriate measures and reporting of results and conclusions. 
The majority of studies considered potential confounding variables such as age, years 
of education, estimated premorbid intellect and mood. Common areas of weakness 
included the method of subject or comparison group selection (such as not explicitly 
stating whether participants had a known incentive to feign or not using clinical 
classification tools for the diagnosis of dementia); the description of subject 
characteristics (for example not specifying use of validated measures to assess 
dementia severity); use of an appropriate sample size (or vastly differing sample 
sizes between experimental and comparison groups) and the explicit description of 
analytic methods.  
Description of findings 
Classification accuracy of individual measures: It was possible to examine pooled 
specificity across 11 PVTs. Of these, six were purpose-designed ‘standalone’ 
measures: TOMM (Tombaugh, 1996), Rey Fifteen-Item Test (RFIT) free recall 
(Lezak, 1983, p619), RFIT combination equation (Boone, Salazar, Lu, Warner-
Chacon, & Razani, 2002), Coin in the Hand (Kapur, 1994), Finger Tapping (Arnold 
et al., 2005) and the Dot Counting Test (DCT; Lezak, 1995). The remaining 
measures were ‘embedded’ PVTs: The Repeatable Battery for the Assessment of 
Neuropsychological Status Effort Index (RBANS EI; Silverberg et al., 2007), Digit  
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Table 3: Results of quality appraisal   
Notes: Criteria 5, 6, and 7 from original QualSyst tool (Kmet et al., 2004) excluded as not relevant to current review
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1. Question / objective sufficiently described? 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
2. Study design evident and appropriate? 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
3. Method of subject / comparison group selection or 
source information/input variables described and 
appropriate? 2 2 1 1 2 2 2 2 1 1 2 1 1 2 1 2 1 1 2 2 1 1 1 2 
4. Subject (and comparison group, if applicable) 
characteristics sufficiently described? 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2 2 2 1 2 2 1 1 1 2 
8. Outcome and (if applicable) exposure measure(s) well 
defined and robust to measurement / misclassification 
bias? Means of assessment reported? 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
9. Sample size appropriate? 1 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
10. Analytic methods described / justified and appropriate? 1 2 2 2 2 1 2 1 2 2 2 2 1 1 2 2 2 2 1 2 2 2 2 2 
11. Some estimate of variance reported for the main 
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Span Age-Corrected Scaled Score (ACSS; Babikian et al., 2006), RDS (Grieffenstein 
et al., 1994), Vocabulary Minus Digit Span (Iverson & Tulsky, 2003) and Trail 
Making Test Ratio (TMT; Iverson, Lange, Green, & Franzen, 2002). The results of 
this analysis are shown in Table 4 and Figure 2. The Repeatable Battery for the 
Assessment of Neuropsychological Status Effort Scale (RBANS ES; Novitski et al., 
2012), Medical Symptom Validity Test (MSVT; Green, 2004), Non-verbal MSVT 
(NV-MSVT; Green, 2008) and WMT (Green et al., 1996) were also assessed, 
however, as they were found to utilise specific algorithms to assess patients with 
dementia or suspected dementia (unlike other PVTs where traditional cut-offs are 
applied regardless of diagnosis), they are described separately below.  
Only three of the measures identified, Vocabulary Minus Digit Span, the 
TMT Ratio and Coin in the Hand, met or exceeded the 90% threshold for appropriate 
specificity in a dementia population. All studies investigating Vocabulary Minus 
Digit Span demonstrated the same specificity of 97% (Iverson & Tulsky, 2003; Dean 
et al., 2009; Kiewel et al., 2012). The latter two studies accounted for 88% of the 
total pooled sample, however, between them included only seven patients with 
‘severe’ dementia. Kiewel et al. (2012) highlight that the WAIS Vocabulary measure 
is rarely administered in more severe cases so it is possible that specificity rates were 
inflated as the full spectrum of dementia severity was not represented. The two 
studies examining the TMT Ratio similarly found consistently high specificity (95% 
in Merten et al., 2007; 99% in Bortnick et al., 2013). The Bortnick et al. (2013) 
paper, however, also reported sensitivity values of 0% for this measure, which, if 
replicated, would raise questions about the utility of this measure as a PVT as it is 
unable to identify invalid performance. The Coin in the Hand was explored across 
two studies again demonstrating consistently high specificity (88% in Rudman et al.,  
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Table 4: Results of classification accuracy analysis 
 
 
 
 
 
 
Measure Cut-off Total pooled 
N 
Specificity 
(%) 
95% CI 
Vocabulary – Digit Span  
(k = 3) 
 
> 5 304 97 95 – 99 
TMT (k = 2) Ratio of A:B 
completion time 
<1.5 
 
62 97 93 - > 100 
Coin in the hand (k = 2) 
 
≤ 7 87 92 86 – 98  
Digit Span ACSS (k = 3) 
 
≤ 5 352 79 75 - 83 
RDS (k = 4) 
 
≤ 6 586 79 76 - 82 
Finger tapping (k = 2) Men ≤ 35 
Women ≤ 28 
 
86 73 64 - 82 
TOMM T2 (k = 8) 
 
< 45 315 70 64 – 74 
RBANS EI (k = 4) 
 
> 3 445 60 55 - 65 
DCT (k = 2) ≥ 17 combination 
score 
 
117 50 41 - 59 
RFIT (k = 2) Free recall < 9 
 
130 42 34 - 50 
RFIT (k = 2) Combination 
equation < 20 
 
73 10 3 - 17 
 
Notes: k = number of studies; TMT = Trail Making Test; Digit Span ACSS = Digit Span Age Corrected 
Scaled Score; RDS = Reliable Digit Span; TOMM T2 = Test of Memory Malingering Trial 2; RBANS EI = 
Repeatable Battery of Neuropsychological Status Effort Index; DCT = Dot Counting Test; RFIT = Rey 
Fifteen Item Test 
35	
	
 
Figure 2: Classification accuracy of individual measures with confidence intervals 
 
Notes: TMT = Trail Making Test; Digit Span ACSS – Digit Span Age Corrected Scaled Score; RDS = 
Reliable Digit Span; TOMM T2 = Test of Memory Malingering Trial 2; RBANS EI = Repeatable 
Battery of Neuropsychological Status Effort Index; DCT = Dot Counting Test; RFIT FR = Rey Fifteen 
Item Free Recall; RFIT Comb = Rey Fifteen Item Combination Equation.  
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2011, to 96% in Schroeder et al., 2012), however, the small pooled sample size (n = 
87) means that these results should be interpreted with caution.   
All other PVTs showed pooled specificity rates below 90%. The TOMM, 
which is the most widely studied PVT in this population (and the most widely used 
in UK clinical neuropsychological practice; McCarter et al., 2009), obtained an 
overall specificity on Trial 2 of 69% across eight studies. Values across studies 
ranged from 24% (Teichner & Wagner, 2004) to 79% (Walter et al., 2014) 
suggesting significant variability in findings but no indication that this measure could 
be used with confidence in this population.  Similar inconsistency was noted in the 
RBANS EI, for which overall specificity was 60% with values ranging from 41% 
(Dunham, Shadi, Sofko, Denney, & Calloway, 2014) to 70% (Bortnick et al., 2013). 
This measure had a large overall pooled sample size (n = 445) across four studies. 
Given that one of the stated principles of the RBANS is to be a ‘standalone core 
battery for the detection and characterisation of dementia in the elderly’ (Randolph, 
1998), it is of importance that the PVT embedded within the battery is one which is 
able to detect valid performance in a dementia population. The results of this 
analysis, however, suggest that use of this measure with conventional cut-offs could 
lead to high rates of false positive classification. 
Data from two embedded measures calculated from WAIS Digit Span indices 
found comparable pooled specificity values. An overall classification accuracy of 
79% was found for the Digit Span ACSS, with values ranging from 73% (Dean et al., 
2009) to 95% (Iverson & Tulsky, 2003). Although again failing to reach the 90% 
mark, this measure does appear more robust to misclassification that the RDS, which 
achieved an overall value of 79% with a range from 70% (Dean et al., 2009) to 87%  
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(Loring et al., 2016). This may be related to the fact that Digit Span ACSS is 
adjusted for age, whereas RDS uses raw scores (Dean et al., 2009).  
The RFIT had two indices that it was possible to assess for classification 
accuracy: Free Recall and Recognition. Small overall sample size for the latter (n = 
73) means that the results should be interpreted with caution. Free Recall had a 
pooled specificity of 42% with a range from 28% (Bortnick et al., 2013) to 45% 
(Dean et al., 2009). The Recognition equation only achieved 10%, with a low of 0% 
(Bortnick et al., 2013) and a high of 14% (Dean et al., 2009). After the TOMM, the 
RFIT is the most commonly used PVT in clinical practice in the UK (McCarter et al., 
2009): these results strongly imply that, if traditional cut-offs are used, this an 
inappropriate tool for use in populations with a potential diagnosis of dementia due 
to high risk of misclassification 
Two studies investigated the DCT using the combination score criterion 
suggested by Boone, Lu & Herzberg (2002). Overall, pooled specificity was 50%, 
with no study demonstrating specificity over 51% (Dean et al., 2009; Boone et al., 
2002). The Finger Tapping measure showed 73% specificity overall, although some 
studies demonstrated values approaching the 90% threshold (87% in Arnold et al., 
2005). Again, small sample sizes for the latter measure are problematic.  
There were a number of measures which were not included in the above 
analysis as results from only a single study were available (see Table 2 for identified 
studies). Of these, only Four Digits Timed (Dean et al., 2009) demonstrated a 
specificity above 90%, however, a small sample size suggests that additional data is 
needed to support these specificity values.  
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Key findings: The data indicate that the majority of measures do not provide adequate 
classification accuracy when conventional cut-off scores are used in dementia 
populations. This includes both standalone and embedded measures, and those 
tapping a range of cognitive domains including recognition memory, processing 
speed and motor speed. Three measures produced specificity above the 90% 
threshold (Vocabulary Minus Digit Span; TMT Ratio; Coin in the Hand) however, 
small sample sizes, limited inclusion of more severely impaired patients and issues 
with sensitivity suggest that these results be interpreted with caution. 
Classification accuracy of PVTs adopting a ‘dementia profile’ 
Four PVTs – the RBANS ES, WMT, MSVT and NV-MSVT - were not 
included in the classification accuracy analysis as they purport to offer specific 
criteria to allow the examiner to differentiate invalid performance due to ‘effort’ and 
that due to genuine memory impairment in the context of a potential differential 
diagnosis of dementia. Two studies examining the RBANS ES demonstrated 
markedly improved specificity when compared to the traditional RBANS EI 
embedded measure. Values ranged between 81% (Dunham et al., 2014) and 96% 
(Burton, Enright, O’Connell, Lanting, & Morgan, 2015) using a cut-off of less than 
12. These data suggest that this measure holds some promise in this population, 
particularly as sample sizes were also adequate (n = 191). Some methodological 
issues were noted, however, such as failure to consider confounding factors such as 
age, education and IQ in both studies and, in the case of Burton et al. (2015), poor 
specification of analytic methods.  
Similar high specificities between 89% and 100% were reported for the 
WMT, MSVT and NV-MSVT measures with the application of the dementia profile 
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algorithms, even in the case of advanced dementia (Howe et al., 2007; Howe & 
Loring, 2009; Henry et al., 2010; Green, Montijo, & Brockhaus, 2011). When the 
dementia profile algorithm is not utilised, specificity on the MSVT and NV-MSVT 
has been shown to be very poor: between 45% and 62% on the MSVT (Rudman et 
al., 2011; Howe et al., 2007) and 33% on the NV-MSVT (Rudman et al., 2011). 
WMT pass rates without use of the dementia profile were less than or equal to 10% 
for bona fide AD patients (Merten et al., 2007).  
Key findings: The RBANS ES, WMT, MSVT and NV-MSVT dementia profile 
algorithms demonstrate consistently higher specificity than standard PVTs, with 
values approaching or exceeding 90% across the range of dementia severity. The use 
of these measures with conventional cut-offs in dementia populations is, however, 
not advised. 
Adjusted cut-off scores and impact on classification accuracy 
As highlighted by Walter et al. (2014), rigid application of conventional PVT 
cut-offs is likely inappropriate in a dementia population and, as evidenced by the 
analysis above, may lead to excessive false positive results. Given this, does 
adjusting the cut-offs for individuals with confirmed or suspected dementia leads to 
an improvement in specificity? A number of studies identified in this review 
addressed this issue.  
For the TOMM, Teichner and Wagner (2004) were unable to reach the 90% 
specificity threshold even when the cut-off was reduced from the conventional cut-
off of less than 45 to less than 40 (86% specificity). By contrast, Bortnick et al 
(2013) found that a threshold of less than 37 for Trail 2 produced a specificity of 
90% whilst maintaining moderate sensitivity at 78%. Specificity was further 
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improved to 95% by lowering the cut-off to less than 28 (Dean et al., 2009). 
Investigating the RFIT, Bortnick et al. (2013) found that specificity above 90% could 
be achieved by adjusting the Free Recall cut-off to less than two and Recognition 
trial to less than three. The latter was corroborated by Dean et al. (2009), however, 
for the Free Recall these authors were unable to achieve a specificity above 90% 
even when the threshold was lowered to less than one.    
The RBANS EI was found to reach the 90% specificity threshold at a cut-off 
of greater than seven (Bortnick et al., 2013). For the RBANS ES Burton et al. (2015) 
adjusted the cut-off to less than seven (as per an earlier study by Schroeder et al., 
2012) and demonstrated improved specificity in both AD and non-AD groups, 
however, only specificity for AD patients reached the 90% threshold.  
The two studies investigating DCT specificity (Boone et al., 2002a; Dean et 
al., 2009) already utilised an alternative criterion suggested by Boone et al. (2002b), 
as opposed to the traditional measure originally put forward by Lezak (1995). Dean 
et al. (2009) highlighted that adjusting the original Boone et al. (2002b) criterion 
from equal to or greater than 17 to greater than 42 enabled specificity to reach the 
90% threshold. Rudman et al. (2011), however, identified the original Lezak (1995) 
index (which looks at the relative discrepancy between grouped and ungrouped dots 
reaction time) as more appropriate in dementia as it takes into account the potential 
reduction in processing speed in this population. Using this criterion, they achieved 
100% specificity. 
For Digit Span derived measures, Dean et al. (2009) found that the Digit Span 
ACSS needed to be reduced to less than three (from less than six) and the RDS to 
less than four (from less than seven) to achieve at least 90% specificity in their 
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dementia sample. Similarly, in an early AD sample Loring et al. (2016) had to reduce 
the RDS cut-off to less than or equal to five to reach a specificity of 97%.  Whilst 
this would reduce the likelihood of false positive identification, the application of 
more conservative cut-offs impacts upon the sensitivity of these measures and thus 
severely limits their ability to detect invalid performance when it occurs (Kiewel et 
al., 2012). 
Key findings: Adjusting PVT cut-offs has been shown to improve the specificity of 
some measures when applied in dementia populations. It is unclear, however, the 
extent to which the sensitivity, and thus utility, of these measures is sacrificed in the 
process of doing so. 
Findings of known groups and simulator studies 
To address the issue of sensitivity, five of the identified studies used a 
‘known groups’ design, whereby clinical samples are compared to clinical groups 
with suspected invalid performance (usually determined by clinical consensus 
following consideration of a range of factors such as implausible patterns of 
response, or deficits disproportionate to functional impairment; Bortnick et al., 2013) 
or to ‘simulators’ (non-clinical samples coached to behave like individuals with 
invalid performance). The latter method enables researchers to address the problem 
of unequal sample sizes, which is a challenge when drawing ‘suspect effort’ 
participants from larger samples of interest. Both designs allow for the estimation of 
sensitivity as it is possible to ascertain how well the measure picks up on the 
individuals ‘known’ to have invalid performance. 
A number of studies highlighted the ‘trade off’ between specificity and 
sensitivity in the RBANS EI, the Finger Tapping Test; RFIT Free Recall and 
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Combination; TMT Ratio and TOMM T2 (Dunham et al., 2014; Arnold et al., 2005; 
Bortnick et al; 2013; Greve et al., 2006), that is, with increased specificity, sensitivity 
to detect invalid performance dramatically reduced in these measures, for some 
measures down to 0% (TMT Ratio; Bortnick et al., 2013). The DCT was shown to 
balance sensitivity and specificity at 75%, but only in the case of mild dementia as 
specificity in moderate dementia at traditional cut-offs dropped to 33% (Boone et al., 
2002). The RBANS ES appeared to be able to maintain moderate levels of both 
sensitivity and specificity (89% and 81%; Dunham et al., 2014), however, this 
measure is designed to account for the types of cognitive impairment frequently seen 
in dementia (that is, the decline of free recall before recognition in amnestic 
disorders), and would therefore likely produce higher false positive rates in a normal 
or non-dementia clinical population (Novitski et al., 2012). In addition, use of a 
coached simulator design in the Dunham et al. (2014) study is methodologically 
problematic, as it is unclear how these results would be reliably applied to clinical 
practice (Greve & Bianchini, 2004).  
Key findings: Balancing sensitivity and specificity of PVTs in dementia populations 
is a significant challenge, and calls into question the clinical utility of these measures 
if they are unlikely to detect invalid performance when it is present. Using measures 
with dementia profile algorithms may mitigate this issue, however, further research 
using clinical populations is required. 
Discrepancies in classification accuracy between different severities of dementia  
Ten studies (Boone et al., 2002; Howe et al., 2007; Howe & Loring, 2009; 
Dean et al., 2009; Rudman et al., 2011; Kiewel et al., 2012; Bortnick et al., 2013; 
Walter et al., 2014; Burton et al., 2015; Loring et al., 2016) compared the 
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performance of a range of measures across different severities of dementia. The 
studies utilised different methods of categorising patients as mild, moderate and 
severe, for example Dean and colleagues (2009) use Mini-Mental State Examination 
(MMSE; Folstein, Folstein, & McHugh, 1975) scores of 21-30 for ‘mild’, 15-20 for 
‘moderate’ and less than 15 for ‘severe’. By contrast, Walter et al. (2014) utilised 
RBANS standard scores: ‘Moderate to Severe’ dementia was a score between 56 and 
77, and these were compared to MCI patients (scores between 77 and 85) and 
cognitively intact controls (85 to 112).  
In a large study covering 12 PVTs, Dean et al. (2009) noted that their ‘mild’ 
sample failed an average of 36% of PVTs, with proportions increasing to 47% for the 
‘moderate’ sample and 83% for ‘severe’. Worst performing measures in this study 
were RFIT, TOMM, b-Test, RAVLT equation, Rey-Osterrieth equation and Rey-
Osterreith/RAVLT equation, which classified none of the more severely impaired 
patients.  Other studies similarly found statistically significant differences in 
classification accuracy between milder and more severe groups. This was the case for 
the TOMM T2 (Walter et al., 2014; Rudman et al., 2011); RFIT (Rudman et al., 
2011), Coin in the Hand (Rudman et al., 2011); DCT (Boone et al., 2002; Rudman et 
al., 2011), MSVT (Rudman et al., 2011) and NV-MSVT (Rudman et al., 2011). 
RBANS EI scores were similarly found to be correlated with dementia severity, 
where higher EI scores (those suggestive of invalid performance) were associated 
with increased dementia severity (Burton et al., 2015). The same study found no 
significant correlation with dementia severity for the RBANS ES, however, of note is 
that the authors used an adjusted cut-off score to assess the association between 
RBANS ES failure rates and dementia severity but used the conventional cut-off for 
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the RBANS EI. As such, it is unclear if applying a more stringent criterion for the 
RBANS EI would have impacted on the relationship with severity.  
In a study of five WAIS-III Digit Span indices, Kiewel and colleagues (2012) 
found that RDS, Digit Span ACSS, longest digits forward 1 (LDF1) and longest 
digits forward 2 (LDF2) all produced unacceptable false positive error rates with 
increasing dementia severity. The ACSS was found to be useful in ‘mild’ dementia 
(95% specificity), as was Vocabulary Minus Digit Span (also 95% specificity), but 
only the latter held for ‘moderate’ severity patients (100% specificity versus 88% for 
the Digit Span ACSS). The Vocabulary Minus Digit Span index performed similarly 
in the Dean et al. (2009) study, being the only one of the 12 PVTs investigated which 
reached the 90% specificity threshold across all dementia severities. Both authors 
concede, however, that subsamples for patients with ‘severe’ impairments were small 
(N = 7 in Dean et al., 2009) or non-existent (Kiewel et al., 2012) as the Vocabulary 
subtest is rarely administered in cases of more severe impairment. The Loring et al. 
(2016) study further demonstrated that using an RDS cut-off score of less than or 
equal to six only produced adequate specificity (over 90%) in individuals with 
MMSE scores of 23 or more, but their ‘early AD’ sample did not include individuals 
with more severe impairment. Overall, it thus remains unclear if Digit Span indices 
are appropriate for use as PVTs in this population.  
Bortnick et al. (2013) corroborated the Rudman et al. (2011) findings, 
demonstrating 0% specificity on the RFIT Combination Equation across all dementia 
severities. This study also found that three of the four tests explored, RBANS EI, 
TMT Ratio and RFIT Recall, had best specificity when patients had MMSE scores of 
between 21 and 25 but not at scores over 25. This raises an additional query as to 
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whether individuals with milder forms of dementia are at increased risk of being 
misclassified by these measures.  
Key findings: Most measures examined demonstrated diminishing classification 
accuracy with increasing dementia severity, however, the potential for 
misclassification is likely to be problematic across the spectrum of the condition. The 
RBANS ES (dementia specific algorithm) was shown to be robust to severity of 
dementia, however, it is unclear if this is a product of the authors’ use of an adjusted 
cut-off score.  
Discrepancies in classification accuracy across dementia subtypes 
Five studies investigated differences in PVT classification accuracy across 
different diagnoses of dementia (Arnold et al., 2005; Dean et al., 2009; Schroeder et 
al., 2012; Bortnick et al., 2013; Burton et al., 2015; Zenisek et al., 2016). Schroeder 
et al. (2012) was the only study to look at the Coin in the Hand Test, and found that 
the number of test errors were not related to dementia subtype (dementia not 
otherwise specified [NOS], AD, VD, FTD and alcohol-related dementia). 
Conversely, in a study comparing ‘AD’ to ‘non-AD’ dementia, Burton et al. (2015) 
found significant group differences in RBANS EI performance, with failure rates 
higher for individuals with non-AD dementia. Failure rates were comparable 
between the groups on the RBANS ES. The RBANS EI findings were not 
corroborated by Bortnick et al. (2013), who found comparable specificity rates on 
this measure between AD, VD and mixed dementia diagnoses, with marginally 
higher rates in individuals with dementia NOS. The same authors highlighted that the 
RFIT Free Recall and Recognition had inadequate specificity across the diagnoses, 
whereas the TMT Ratio met or exceeded the 90% specificity threshold across all 
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groups. It should be borne in mind that small sample sizes were an issue for this 
study. 
Differences in specificity were also found when comparing AD, VD and FTD 
(Dean et al., 2009). Worst performing measures across all dementia subtypes were 
RFIT (Free Recall and Recognition); RAVLT equation, Rey-O equation and REY-
O/RAVLT. Only Vocabulary Minus Digit span was found to afford specificity above 
90% in all three patient groups. Three Digits Timed and Four Digits Timed had 
100% specificity in AD and VD, but both had poor performance in FTD (33% and 
67% respectively). Conversely, VD patients achieved only 43% specificity with 
traditional cut-offs on the Finger Tapping test, whereas both AD and FTD patient 
groups had 100% specificity on this measure. Again, many of the subgroups were 
small and the authors further note that there was a lack of demographic equivalence 
between them, for example FTD patients having significantly higher MMSE scores 
than AD patients. However, the Finger Tapping data replicates the results of an 
earlier study by Arnold et al. (2005), which highlights the utility of this measure in 
AD but not non-AD populations.  
The RDS was explored in four dementia subgroups by Zenisek et al. (2016): 
AD, VD, Dementia with Lewy bodies (DLB) and FTD. At the conventional cut-off 
of less than or equal to six, the RDS did not achieve specificity over 90% in any of 
the groups however, differences between diagnoses were noted with values ranging 
from 73% in FTD to 85% in DLB. Again, sample sizes for all but the AD group were 
small.  
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Key findings: Overall, the data point to the potential influence of pathology on PVT 
performance. The results should, however, be viewed as preliminary due to small 
sample sizes. 
 
Discussion 
In summary, classification accuracy analysis of 11 PVTs demonstrated that in 
dementia patients without clear external incentives to underperform, most measures 
had inadequate specificity (under the 90% threshold). This included both standalone 
and embedded PVTs which are commonly used in UK clinical neuropsychological 
practice, such as the TOMM, RFIT, DCT, RBANS EI, Digit Span ACSS, RDS, 
WMT, MSVT and NV-MSVT. Only Vocabulary Minus Digit Span, TMT Ratio and 
Coin in the Hand achieved an appropriate level of specificity, suggesting that, of the 
measures examined, these PVTs are the most likely to detect valid performance in a 
dementia population. However, methodological issues with these studies mean that 
these results should be interpreted with caution. Where PVTs have been adapted or 
developed for use in dementia, specificity rates have improved. The RBANS ES 
(Novitski et al., 2012) and dementia profiles of the WMT, MSVT and NV-MSVT 
(Green et al., 2011; Howe et al., 2007; Howe & Loring, 2009; Henry et al., 2010) all 
demonstrated promise for use as PVTs in this population, with specificity values 
approaching or exceeding the 90% threshold.  
The findings of this review have revealed an inverse relationship between 
PVT classification accuracy and dementia severity, with almost all measures 
demonstrating significantly worse specificity in more advanced dementia. This raises 
a broader question about whether the tests are measuring what they purport to 
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measure. The fundamental assumption of a PVT is that it will be insensitive to 
cognitive dysfunction (Tombaugh, 1997): this review has demonstrated that this is 
not necessarily the case across a range of measures examining multiple cognitive 
domains, with the possible exception of the aforementioned PVTs which have been 
specifically adapted for this population. In routine clinical practice, the need for 
accurate PVTs likely diminishes with increasing dementia severity as obvious 
functional or behavioural impairments reduce the likelihood of patient 
misclassification (Loring et al., 2016; Bortnick et al., 2013). Nonetheless, these 
results strongly imply that PVTs are less robust to cognitive impairment than 
generally assumed. 
PVT specificity was further shown to vary related to dementia subtype. 
Different dementia subtypes differ in their cognitive profiles; for example, compared 
to subcortical VD patients, AD patients are typically more impaired in episodic 
memory and less impaired in semantic memory, executive functioning, attention and 
visuospatial and perceptual skills (Graham, Emery & Hodges, 2004). It makes 
intuitive sense, therefore, that specificity will be lower for measures which tap the 
cognitive domain affected by a particular dementia subtype. For example, it has been 
suggested that the motor cortex is relatively spared in the early stages of AD, which 
may have contributed to the high pass rate on the Finger Tapping measure in this 
population versus VD and non-AD patients (Arnold et al., 2005; Dean et al., 2009). 
One might also query if the poor performance of FTD patients compared to AD and 
VD patients on the Three- and Four Digits Timed tasks (Dean et al., 2009) is related 
to pathology in the frontal or anterior temporal lobes and concomitant effects on 
executive processes, however, this would require further investigation. More 
generally, Rudman et al. (2011) found that new learning ability was the strongest 
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predictor of failure across the TOMM, RFIT, MSVT and NV-MSVT. It is perhaps 
unsurprising, therefore, that dementia populations, who frequently exhibit difficulties 
in this domain (Aretouli & Brandt, 2010) would fail these measures as all have a 
learning and recall component. This points to the need to consider the 
appropriateness of the measure in light of the individual’s subjective cognitive 
complaints and in the context of the neuropsychological assessment as a whole. 
Clinical implications 
The conclusions of this review have a number of implications for clinical 
practice. Firstly, the use of the aforementioned measures with traditional cut-offs is 
not recommended in dementia (or suspected dementia) populations due to the high 
risk of making a false positive error (classifying performance as invalid when it is 
not). Although adjusting cut-offs generally leads to an improvement in specificity, 
the results of known-groups and simulator studies indicate that applying more 
stringent thresholds will likely have a knock-on effect on test sensitivity (the ability 
to correctly identify invalid performance). Although advice regarding PVT cut-offs is 
generally to focus on specificity “while letting the sensitivity chips fall where they 
may” (Greve & Bianchini, 2004; p. 536), making dramatic modifications to 
conventional thresholds to account for the particular challenges of testing a dementia 
population is likely to significantly limit their clinical utility. Using measures with 
profile algorithms designed to account for the particular difficulties observed in 
dementia appears to offer the most reliable means of assessing performance validity 
in this population, with preliminary evidence for the RBANS ES suggesting that 
sensitivity is not hugely compromised (Dunham et al., 2014). Of note is that this 
measure has been found to be unsuitable for use in cognitively intact individuals 
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(Novitski et al., 2012), which limits its utility to situations where there is a suspected 
or confirmed diagnosis of dementia.  
The fact that many PVTs were found to be sensitive to cognitive impairment 
raises questions about the use of PVTs more generally: if specificity levels are 
problematic in severe dementia then can the same be said for other neurological 
populations such as severe brain injury or intellectual disability? These data appear 
to illustrate that there comes a point at which the PVT stops measuring performance 
validity and begins to measure cognitive dysfunction, which clearly invalidates the 
test (Walter et al., 2014). These findings underscore the importance of robust 
biopsychosocial formulation in the context and information should be triangulated 
from multiple sources (for example results of PVTs, cognitive test scores, patient 
self-report, consideration of psychological state and co-morbid diagnoses) prior to 
reaching an opinion on an individual’s performance validity (McMillan et al., 2009).  
Methodological critique of the studies 
A number of methodological issues have been raised through examination of 
the data contributing to this review. Some of these weaknesses are inherent to the 
study of dementia populations, such as the use of mixed etiology groups and lack of 
consistency in diagnostic categorisation (Kiewel et al., 2012). As it was not possible 
to randomly assign patients to groups internal validity was reduced across all studies 
(Sollman & Berry, 2011). Many studies further had small overall sample sizes and 
compared groups which were unequal in size. For example, Dean et al. (2009) 
included some subgroups with only one participant, which clearly limits how these 
findings might be generalised to the population as a whole. Suggested cut-offs based 
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on these small sample sizes may also be less stable, and so less confidence can be 
placed on accurate classification should they be used (Greve & Bianchini, 2004).  
Seven studies also failed to adequately control for confounding variables such 
as age, estimated premorbid education or mood. Individual differences should always 
be considered when interpreting the results of neuropsychological measures, whether 
they are PVTs or assessments of particular cognitive domains (Duff et al., 2011). For 
example, it has been shown that scores on the RBANS EI are influenced by age and 
education (Duff et al., 2011), and that depressed older adults are more likely to be 
classified as ‘suspect effort’ on this measure (Barker et al., 2010). As such, the fact 
that a third of studies reviewed failed to establish demographic equivalence between 
groups is problematic.  
Incomplete information regarding sensitivity of the identified measures is a 
major limitation of these studies, as only five studies utilised a design which would 
allow for an estimate of sensitivity to be produced, and these data were largely based 
on non-dementia comparison groups. As has been highlighted, PVTs have limited 
practical utility if they do not capture invalid performance when it occurs: the focus 
may be on specificity however, in reality, any PVT should offer a balance between 
the two (Bortnick et al., 2013). Further known-groups studies using dementia 
subsamples would address this issue and help to extend our understanding of the 
impact of adjusting cut-off scores for use in this population.   
A key conceptual issue with this review rests on the assumption that PVT 
failures represent ‘false positives’ as the clinical groups are ‘bona fide’ dementia 
patients. PVT failures may well be ‘false positives’, but only if one assumes that the 
PVT is singular in scope. Is it possible, however, that there are other circumstances 
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which might produce ‘false positives’ over and above how the person applies 
themselves on the test? In reality, a range of factors may influence PVT failure in 
dementia samples, some of which have been illustrated in this review, for example 
severe cognitive impairment and dementia subtype. Other factors, however, must 
also be taken into consideration with this population (and, indeed, with all 
populations who present for neuropsychological assessment), including physical 
health issues (such as chronic health problems, polypharmacy and sensory 
impairments; Storandt, 1994) and factors affecting engagement (for example 
psychiatric distress or fatigue; Walter et al., 2014). Indeed, as Suesse et al. (2015) 
emphasise, there may be no such thing as a verifiable false positive on PVTs and, as 
such, they opt to refer to ‘unexplained failures’. Again, this points to the critical 
importance of using PVT results as just one contributing element in the broader 
clinical formulation to ensure that inappropriate conclusions are not drawn. 
Limitations of the review 
The results of this review should be considered somewhat tentative for a 
number of reasons. Firstly, the results of the classification accuracy analysis were 
based on a small number of studies which did not cover the full range of PVTs used 
in clinical practice. It furthermore did not look to examine the classification accuracy 
of measures used in combination. Clinical guidelines (Bush et al., 2005; McMillan et 
al., 2009) emphasise the importance of using two or more PVTs in combination to 
reduce the risk of false positives (Larrabee, 2014). Future studies investigating 
optimal combinations of PVTs for use in a dementia population would provide 
clinically useful information (Vickery et al., 2001). It is also acknowledged that the 
weighted means approach presents some methodological issues, for example poor 
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control of extraneous variables. Ideally, specificity data should also be analysed 
alongside sensitivity data as there is an inverse relationship between the two, 
however, this was not possible with this dataset due to the issues outlined above. 
Nonetheless, it is argued that the generation of pooled specificity can provide 
clinicians with the most likely estimate of the classification accuracy of these 
measures until alternative methods of analysis are available (Deville et al., 2002).  
A key issue to also consider is that even with the calculation of specificity 
and sensitivity values, these indicators cannot provide a full impression of the 
accuracy of clinical decision-making using a particular PVT at a particular cut-off 
(Vickery et al., 2001). To fully inform the clinical application of PVTs with a given 
population in a given setting, one must also consider the potential base rate of invalid 
performance in the population being assessed (McMillan et al., 2009). It is only with 
this information that one can begin to determine what proportion of a test’s 
classifications are likely to be accurate: these values are referred to as the positive 
and negative predictive powers of a test (Sollman & Berry, 2011). To the author’s 
knowledge, base rate information regarding the prevalence of invalid performance in 
clinical dementia settings has not been established, and indeed the PVT literature as a 
whole frequently fails to examine the influence of base rates when estimating the 
accuracy of prediction models (Rosenfeld, Sands & Van Gorp, 2000). Classification 
accuracy statistics and base rate data are interdependent, and it is recommended that 
without it clinicians should be cautious about interpreting performance validity data, 
and where possible acknowledge limitations in assessment methods by providing 
probability estimates or possible error rates (Rosenfeld et al., 2000). Understanding 
the base rate of invalid performance in clinical neuropsychological practice is 
therefore an important next step in validating some of the findings from this review. 
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Abstract 
Aims: Performance validity tests (PVTs) were initially designed to assist the 
actuarial judgement of test-taking behaviour in medicolegal settings. Less is known 
about the performance of NHS patient populations on PVTs. The study aimed to 
establish the base rate of failure on commonly-used PVTs in a sample of acquired 
brain injury patients representative of those accessing NHS services. A secondary 
aim was to examine differences between PVT pass and fail groups on cognitive 
testing. 
Method: Clinical neuropsychological assessment data was gathered across three 
NHS acquired brain injury services. Data included at least one embedded PVT 
(derived from the WAIS Digit Span) and one standalone PVT (the Test of Memory 
Malingering [TOMM]). Individuals passing and failing PVTs were compared in 
terms of demographic variables and scores on tests of cognitive function. 
Results: The base rate of TOMM failure was 10%. Only 4% of patients failed the 
TOMM plus an additional embedded PVT. Individuals failing PVTs demonstrated 
reduced scores on cognitive testing.  
Conclusions: Findings suggest that whilst failure on multiple PVTs is relatively rare, 
a substantial minority of patients in clinical settings will fail one PVT. Individuals 
failing PVTs were more likely to have lower scores on tests of cognitive function, 
however, the factors underpinning these supressed scores were unclear. More 
research is required to delineate the contributions of cognitive and psychological 
variables to PVT failure. It is thus recommended that PVTs be used with caution in 
clinical settings.  
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Introduction 
   Fundamental to the practice of neuropsychology is the assumption of a 
relationship between an individual’s performance as measured by 
neuropsychological tests and a condition of the brain (Lezak, Howieson, & Loring, 
2004). Cognitive testing is employed because it is understood that the resulting 
scores, when taken as part of a biopsychosocial neuropsychological formulation, will 
inform the clinician’s understanding of the individual and their needs. As such, it is 
important for clinicians to critically consider the reliability of their measures to 
enable judgements regarding whether scores represent a valid estimate of the 
individual’s functioning at the time of testing.  
   The quality of the contributing test data is impacted by broad range of 
factors, including the test-taking environment, the psychometric properties of the 
test, the proficiency of the examiner and myriad influences acting upon the 
examinee. As cognitive tests are performance-based assessment methods the 
individual’s test-taking behaviour is of particular relevance, as distortions in 
performance could result in scores which are not representative of ‘true’ deficits 
(Millis, 2009). Examinee ‘effort’ is a behavioural factor gaining increasing 
prominence in the literature (McMillan et al., 2009; McCarter, Walton, Brooks, & 
Powell, 2009). Clinical observation alone has been shown to be an unreliable method 
of discriminating which examinees are exerting ‘adequate effort’ in assessments, 
despite studies indicating high levels of clinician self-rated confidence in their 
judgements (Heaton, Smith, Lehman, & Vogt, 1978; Dawes, Faust, & Meehl, 1989; 
Faust, Hart, Guilmette, & Arkes, 1998). Clinicians are therefore at risk of making 
false positive errors by concluding that supressed scores are due to brain damage 
when this is not the case (Hampson, Kemp, Coughlan, Moulin, & Bhakta, 2014). As 
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such, the empirical validation of examinee performance is crucial for good practice 
(McMillan et al., 2009). 
The assessment of performance validity 
   Research in the area of performance validity assessment initially focused on 
forensic and medicolegal samples (Merten, Bossink, & Schmand, 2007). These 
populations have clear issues of prospective secondary gain, which presented a 
challenge for clinicians wishing to obtain an unbiased impression of the individual’s 
deficits in order to distinguish between potential malingerers (individuals producing 
false or grossly exaggerated symptoms motivated by external incentives; Slick, 
Sherman, & Iverson, 1999; American Psychiatric Association, 2000) and legitimate 
claimants. The presence of superordinate moderating variables (such as the potential 
for secondary gain) has been demonstrated to exert a significant impact on an 
individual’s clinical presentation across a range of domains including cognitive, 
physical, sensory and psychiatric symptoms. A meta-analysis by Belanger, Curtiss, 
Demery, Lebowitz, & Vanderploeg (2005) noted that patients with mild traumatic 
brain injury (mTBI) involved in litigation proceedings were more likely to remain 
symptomatic or deteriorate over time compared to non-litigants who recovered on 
average by three months post-injury. The presence of litigation was found to be the 
key discriminating factor influencing the patients’ reported symptomatology.  
   The practice of empirical performance validity testing has emerged in this 
context, motivated by increased recognition of the frequency of suboptimal 
performance in these settings and the concomitant need to provide a more stringent 
means of identifying this behaviour when it occurs (Strauss, Sherman, & Spreen, 
2006, p. 1145). Measures have thus been developed which can be used to assist 
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clinical judgements regarding the reliability of the test data, known variously as 
‘effort tests’, ‘performance validity tests’ (PVTs), ‘symptom validity tests’ (SVTs) or 
measures of ‘response bias’. All purport to be sensitive to test-taking ‘effort’ whilst 
remaining insensitive to acquired cognitive impairment. PVTs appear subjectively 
difficult to the examinee but have been devised such that even individuals with 
globally reduced cognitive ability are mostly able to perform at or near ceiling 
(Tombaugh, 1997). Normative data from bona fide clinical groups, litigating samples 
and identified malingerers has contributed to the formation of ‘cut-off’ scores, that is, 
identification of the lowest possible score that the individual must obtain to ‘pass’ the 
test. Scoring below this threshold (and therefore below most clinical patients but 
similarly to those simulating impairment or engaging in probable malingering; 
Holdnack, Millis, Larrabee, & Iverson, 2013) would raise questions about 
performance across the test battery as it is assumed that this indicates a non-
neurological influence on performance (Locke, Smigielski, Powell & Stevens, 2008).  
   It should be borne in mind that whilst test failure may reflect a purposeful 
intention to deceive through underperformance, it may equally be related to other 
factors, for example abnormal arousal, iatrogenic symptoms, somatoform disorders, 
or that examinees have a benign lack of interest in psychometric testing (Bunnage, 
Eichinger, Pearce, Duckworth & Newson, 2008; McMillan et al., 2009). The 
ubiquitous term ‘effort testing’ is therefore something of a misnomer which reflects 
the origins of these measures in the medicolegal field. In a clinical context, to 
characterise an individual as ‘malingering’, or indeed as exerting ‘poor effort’, on the 
basis of PVT failure alone may represent a serious false positive error with 
significant negative consequences (for example denial of benefits or treatment). 
Neuropsychological tests are only able to measure behaviour and not intent (Boone 
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et al., 2002), which is essentially unknowable (Suesse, Wong, Stamper, Carpenter, & 
Scott, 2015). To reflect a broader understanding of this construct which may be more 
applicable to clinical practice, the terms ‘performance validity’ and associated 
‘performance validity tests’ (PVTs) will be utilised in this paper as per Larrabee 
(2012). PVTs are differentiated from ‘symptom validity tests’ (SVTs) in that they 
pertain specifically to the validity of cognitive test performance, as opposed to the 
validity of self-reported symptomatology which is outside the scope of the current 
paper.  
Performance validity tests (PVTs) 
   A range of measures have been designed and validated for the assessment 
of performance validity.  Some have been developed specifically for this purpose, for 
example the Test of Memory Malingering (TOMM; Tombaugh, 1996). These 
frequently take the form of forced-choice recognition memory measures 
administered as stand-alone tests within a larger neuropsychological battery, where 
scoring significantly below chance is viewed as indicative of ‘non-credible’ 
performance, but where thresholds well above this level may still indicate ‘invalid’ 
performance (Tombaugh, 1996; Frederick & Speed, 2007; Boone, 2007). In 
validation studies, the TOMM has been shown to be relatively insensitive to a range 
of physical and affective disorders in addition to age and level of education 
(Tombaugh, 1996; Rees, Tombaugh, Gansler, & Moczynski, 1998; Rees, Tombaugh, 
& Boulay, 2001; Ashendorf, Constantinou, & McCaffrey, 2004; Iverson, Le Page, 
Koehler, Shojania, & Badii, 2007).  
   Using ‘embedded’ performance validity measures is a second approach. 
These measures are derived from existing neuropsychological tests that have 
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additional value in identifying possible ‘non-credible’ performance, meaning that 
they serve a ‘double duty’ and therefore do not increase testing time in addition to 
being less vulnerable to coaching (McMillan et al., 2009; Heilbronner et al., 2009). 
One example is the Reliable Digit Span (RDS), derived originally from the Wechsler 
Adult Intelligence Scale - Revised (WAIS-R; Wechsler, 1981) Digit Span subtest 
(Greiffenstein, Baker, & Gola, 1994). This is the sum of the longest string of digits 
repeated without error over two trials in both forward and backward conditions, 
where a score of less than or equal to six is generally accepted as indicating 
suboptimal performance (Schroeder, Twumasi-Ankrah, Baade & Marshall, 2012). In 
a study of 17 embedded and three stand-alone indices,  Miele, Gunner, Lynch, & 
McCaffrey (2012) found that compared to individuals passing the RDS, examinees 
failing the RDS were over 11 times more likely to be identified as ‘suboptimal effort’ 
(characterised via failure on a stand-alone PVT), suggesting that it is a useful 
predictor of invalid performance. These authors also demonstrated, however, that 
embedded measures overall had reduced sensitivity (ability to detect true positives) 
and specificity (ability to detect true negatives) as compared to stand-alone PVTs. 
This is perhaps unsurprising given that embedded measures are derived from tests 
originally designed to assess ability as opposed to ‘effort’ (Schutte & Axelrod, 
2012). With this in mind, use of a combination of embedded and stand-alone 
measures (a ‘multi-method, multi-test’ approach) has been recommended for the 
assessment of performance validity in neuropsychological evaluation by both the 
British Psychological Society (BPS; McMillan et al., 2009) and the American 
Academy of Clinical Neuropsychology (AACN; Heilbronner et al., 2009).  
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What can PVT failure tell us about neuropsychological test data? 
   Research indicates that the presence of PVT failure undermines the 
confidence that can be placed in the remaining test data. For example, Fox (2011) 
conducted an archival study of 220 cases and found that when just one PVT was 
failed, there was no correlation between performance on cognitive tests and 
documented brain damage. Similarly, Green, Rohling, Lees-Haley, & Allen (2001) 
found that 53% of the variance in neuropsychological test data from 904 
compensation claimants could be explained by ‘effort’, compared to only 11% 
attributed to years of education and 4% to age. This was corroborated by Victor, 
Boone, Serpa, Buehler, & Ziegler (2009): significantly lower Full Scale IQ was 
noted in ‘non-credible’ versus ‘credible’ patients (that is, those failing versus passing 
PVTs), which was thought to be secondary to higher levels of response bias as 
education levels were not significantly different across the groups. In a UK 
compensation-seeking sample, Moss, Jones, Fokias, & Quinn (2003) likewise found 
no evidence of a relationship between head injury severity and IQ and memory 
indices in individuals failing an established PVT. PVT failure thus appears to capture 
an element of test-taking behaviour which is linked to achievement on cognitive 
testing.  
The use of PVTs in clinical settings 
   With an improved understanding of how superordinate factors impact upon 
neuropsychological test data, it is increasingly recognised that examination of 
performance validity is necessary in all clinical assessments which aim to understand 
brain-behaviour relationships, contribute to diagnoses or formulate treatment 
recommendations (Kemp et al., 2008). In line with this, professional guidelines in 
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both the US (Bush et al., 2005; Heilbronner et al., 2009) and UK (McMillan et al., 
2009) emphasise that performance validity testing should no longer be the sole 
domain of clinicians working in forensic or medicolegal settings, and advocate 
incorporating PVTs as standard in clinical neuropsychological practice. The direct 
application of existing knowledge regarding PVTs, however, presents a challenge to 
clinicians when much of the normative reference data has been derived from 
litigating populations. The use of PVTs in clinical settings places greater demand on 
a measure’s predictive validity, as the clinician is attempting to distinguish between 
symptom amplification and clinical syndrome as opposed to between malingering 
and ‘normalcy’ (Merten, Bossink, & Schmand, 2007). Unfortunately, little data from 
clinical samples which could be directly applied to general clinical or NHS 
populations is so far available, and thus many clinicians in the UK, concerned about 
test reliability and potential for misclassification, continue to rely on clinical 
judgement as a means of assessing performance validity (McCarter et al., 2009; Hall, 
Worthington, & Venables, 2014; Suesse et al., 2015).    
Improving classification accuracy 
   So far it has been highlighted that there are empirical means of assessing 
performance validity, and that this identification is key to establishing the reliability 
and validity of the neuropsychological data as a whole. However, existing PVTs are 
imperfect measures. Depending on the sensitivity and specificity levels of the test(s) 
employed, there is a greater or lesser risk of falsely identifying examinees as having 
invalid performance , or conversely missing examinees who are performing sub-
optimally and so taking invalid results as valid. Of note is that the specificity of these 
measures is often set high in order to reduce the occurrence of false positive results, 
as there are greater consequences for the patient associated with providing a clinical 
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opinion of invalid performance than vice versa. As a result, sensitivity is often 
compromised (Greve & Bianchini, 2004).  This is illustrated in a meta-analysis 
investigating the ability of five PVTs to discriminate between honest responders and 
dissimulators, which found an average specificity of almost 96% but a sensitivity of 
only 56% (Vickery, Berry, Inman, Harris, & Orey, 2001). To mitigate this issue, 
Larrabee (2003) advocates the use of a multivariate failure model, that is, failure on 
two or more PVTs to indicate probable invalid clinical presentation. The finding of 
good sensitivity and specificity for distinguishing ‘credible’ and ‘non-credible’ 
patients on this basis has been demonstrated by Victor and colleagues (2009).  
   Diagnostic accuracy can be further improved by the consideration of the 
prevalence, or ‘base rate’, of the characteristic of interest (that is,invalid 
performance) in the population being examined. There is an established literature 
indicating that low scores are a normal occurrence across a battery of 
neuropsychological tests (for example memory and intelligence tests). Prevalence 
rates are related to inter-individual variability (in factors such as level of intelligence 
and years of education) in addition to test inter-correlations and the number of tests 
administered (Brooks, Holdnack, & Iverson, 2011). In the context of this, Iverson 
and Brooks (2011) highlight that the primacy of deficit measurement as the means of 
analysing neuropsychological test batteries can lead to the (erroneous) attribution of 
low or unexpected test scores to a condition of the brain, making clinicians prone to 
drawing false positive conclusions. Understanding the base rate of low scores across 
batteries is therefore increasingly considered critical for facilitating the advanced 
interpretation of performance. This information can be used together with sensitivity 
and specificity data to allow for the calculation of clinically-relevant probability 
indices such as positive and negative predictive power (PPP and NPP), which reflect 
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the real-world assessment settings in which the results are used (Strauss et al., 2006, 
p.1149) and so provide a more psychometrically robust methodology for test 
analysis. PVTs are subject to the same vagaries of psychometric statistics as other 
neuropsychological tests: just as one low score on a battery of IQ tests cannot be 
considered proof of cognitive impairment, failure on one PVT may not be proof of 
invalid performance if we are unsure to what extent this pattern of results is common 
in a particular assessment setting. In other words, failure to acknowledge the 
influence of local base rates may result in unwarranted confidence that invalid 
performance is present when it is not or vice versa (Rosenfeld, Sands, & Van Gorp, 
2000). Consideration of the frequency of failure on one or more measures in a 
multivariate battery of PVTs in a specific population or assessment setting is 
therefore a central factor in improving clinical classification accuracy.  
Base rates of performance validity test failure  
Medicolegal and forensic samples: Base rates of identified invalid 
neuropsychological performance vary hugely depending on clinical context. In 
settings with external incentives (such as litigation) studies have reported base rates 
from 30 to 50% (Mittenberg, Patton, Canyon, & Condit, 2002; Larrabee, Millis, & 
Meyers, 2009). A survey exploring the clinician-estimated base rate of malingering 
and symptom exaggeration in over 33,500 cases further reported evidence of this in 
29% of personal injury evaluations, 30% of disability evaluations, 19% of criminal 
evaluations and 8% of medical evaluations, the highest estimated prevalence being in 
personal injury litigants with mTBI (Mittenberg et al., 2002).  
Focusing specifically on base rates of PVT failure, Fox (2011) found that 
35% of patients in a mixed clinical and litigating setting failed the Word Memory 
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Test (WMT; Green, 2003) or Computerised Test of Attention and Memory (CTAM; 
Fox, 2009). Similarly, a base rate of 42% failure on two or more stand-alone PVTs 
tests was reported by Miele and colleagues (2012) in a medicolegal setting. Moss et 
al. (2003) further demonstrated an overall TOMM failure rate of 31% in a UK 
sample of 78 patients assessed in connection with compensation claims, highlighting 
that the prevalence of invalid performance may be as frequent in UK medicolegal 
settings as indicated in the North American evidence base.  
Clinical samples: It is perhaps not surprising that high base rates of invalid 
performance are found in forensic settings where there is clear potential for 
secondary gain. Significantly less data exists to inform our understanding of base 
rates of PVT failure in clinical populations. Here the majority of patients are non-
litigating but nonetheless issues of secondary gain may still be present, for example 
where the individual is receiving disability benefits or discounted taxation rates. It is 
thus increasingly recognised that ‘effort’, symptom exaggeration and invalid 
performance may still be complicating factors of neuropsychological assessment in 
these contexts (McCarter et al., 2009).   
   A study by Locke and colleagues (2008) investigating base rates of TOMM 
failure in a treatment-seeking outpatient brain injury rehabilitation population is 
relevant in this regard. They found that almost 22% of the sample performed below 
cut-off on this measure, and additionally demonstrated a significant relationship 
between lower TOMM scores and lower cognitive test scores which they established 
was not secondary to the severity of the cognitive impairment, corroborating the 
Moss et al. (2003) findings in UK compensation claimants. Similarly, a retrospective 
analysis of WMT performance in 132 non-litigating NHS patients without clear 
external incentive found that 26% of patients failed when using the least stringent 
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cut-off on this measure. Failure rates rose to 37% using the most stringent cut-scores 
(Bunnage et al., 2008). A more recent UK NHS study by Hampson et al. (2014) 
examined the base rates of failure across seven PVTs (including the WMT and 
embedded measures from the Wechsler Adult Intelligence Scale, 3rd Edition [WAIS-
III; Wechsler, 1997a] and Wechsler Memory Scale, 3rd Edition [WMS-III, Wechsler, 
1997b]) and three patient populations: acute brain injury, community brain injury 
and epilepsy. Their findings demonstrated that a ‘significant minority’ of patients 
failed PVTs when using conventional cut-off scores: for example, failure rates on the 
WMT immediate and / or delayed recognition trials were 27%, 35% and 19% in the 
three groups respectively. Community brain injury participants were shown to have 
an overall higher base rate of failure across the different tests - they were also found 
to be more severely impaired than other participants based on their clinical history, 
suggesting that PVT failure may have been related to more significant cognitive 
impairment in this population. Indeed, when the authors re-analysed the WMT 
failure rates using adjusted cut-off scores (based on profile analysis comparing 
participant scores to individuals with identified genuine cognitive impairment) 
failure rates reduced. Finally, a UK study by Hall et al. (2014) also found a false 
positive rate of 18% using the WMT with identified non-malingering mTBI patients. 
This was correlated with reduced verbal memory scores in these patients, suggesting 
that performance below cut-off in these patients may have been indicative of verbal 
processing deficits in this group.  These findings again underscore the importance of 
establishing local base rate data for specific clinical populations.  
   Base rates of failure in non-litigating patients are altered with the 
application of Larrabee’s (2003) more conservative test failure criterion. Meyers and 
Volbrecht (2003) observed that no clinical, non-litigating patients (including patients 
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across a spectrum of injury severity) failed more than one PVT. Victor et al. (2009) 
later demonstrated that 6% of a sample of 66 ‘credible’ patients failed two or more 
PVTs. Davis and Millis (2014), by contrast, found a failure rate of 15% using this 
threshold in a neurological no-incentive group administered seven or eight PVTs. 
Kemp et al. (2008) found a base rate of failure of 11% on two or more PVTs in a UK 
sample of non-litigating neurology patients with medically unexplained symptoms. 
They cite a range of potential mechanisms to account for ‘suboptimal effort’ in this 
subset, including biased information processing due to health beliefs or anxiety, 
somatoform symptoms and non-specific factors such as fatigue or pain. Again, this 
study indicates that factors beyond identifiable incentive may serve to compromise 
PVT performance. Taken in addition to the fact that no assessment setting can be 
characterised as truly incentive ‘free’, this highlights the complexity of this issue and 
the importance of considering performance validity in clinical, as well as litigious, 
contexts. 
   To summarise, it has been demonstrated that base rates of failure on one 
PVT in clinical populations are comparable to those found in studies conducted in 
medicolegal settings. Applying the two or more failure criterion unsurprisingly 
reduces the base rate of PVT failure, however, given that base rates of up to 15% 
have been found, in addition to evidence demonstrating an appreciable reduction in 
false positive error rates as a function of utilising this more conservative threshold 
(Larrabee, 2014), this represents an important consideration for clinical practice. 
Firstly, if an assumption is made that invalid performance rarely occurs outside of 
medicolegal settings, the empirical testing of this construct may be neglected and in 
the process of doing so, a potentially large source of test variance overlooked. In a 
survey of 130 UK-based practicing neuropsychologists, McCarter and colleagues 
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(2009) found that 26% endorsed the statement that symptom validity testing was 
“neither mandatory nor necessary since clinical cases rarely exaggerate” (p. 1060). 
As has been outlined above, performance validity testing should not solely be applied 
to identify symptom exaggeration or malingering. PVTs appear to capture a non-
neurological dimension of performance (Bigler, 2012) and in doing so provide 
information on the validity of test data, thus enabling more robust formulations to be 
drawn up. Without administering measures to assist with analysis of test-taking 
behaviour, patients may be classified as impaired when this is not the case.  
   Secondly, where performance validity testing is conducted, failure of a 
single test or a series of tests may inaccurately be considered clinically significant 
when in fact little is known about how frequently failure might be expected in that 
population. The clinical consequences of this could be substantial. Depending on the 
assessment context, individuals given a false positive diagnosis of ‘suboptimal effort’ 
may be wrongly deprived of social entitlements, be subject to incorrect legal verdicts 
or provided with disadvantageous recommendations (Mossman, Wygant & Gervais, 
2012; McMillan et al., 2009). As such, interpretation of performance validity test 
scores should be conducted with reference to available base rate data best suited to 
the population and assessment context in question. This would enable an indication 
of prevalence of ‘invalid’ scores among examinees with bona fide injuries, thus 
providing an estimate of the likelihood that such scores are false positives (Strauss, 
Sherman & Spreen, 2006, p. 1152).  
Study aims 
   The aim of the present study is to extend the Locke et al. (2008) and 
Hampson et al. (2014) papers and investigate the base rate of PVT failure in a UK 
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sample of NHS patients with acquired brain injuries. A stricter criterion will be 
applied based on the Larrabee (2003; 2014) data supporting the practice of using two 
or more PVT failures as indicative of probable invalid presentation. This would 
inform clinicians as to the frequency of multiple test failure in this population and 
thus allow for more accurate estimation of the likelihood of false positives. To the 
author’s knowledge, this will be the first study to investigate this issue in the UK, 
and would be in line with the research needs identified by  the BPS (McMillan et al., 
2009, p12). It is also the first identified study to consider TOMM performance in this 
context: the TOMM has been identified as the PVT most commonly used in UK 
clinical practice (McCarter et al., 2009) this would therefore represent an important 
addition to the evidence-base. 
   A secondary aim of this study is to ascertain if there are differences 
between pass and fail groups in terms of performance on cognitive testing. 
Considering the US data from Fox (2011) highlighting that PVT failure invalidates 
expected brain-behaviour relationships, in addition to research indicating a strong 
relationship between test failure and reduction in overall neuropsychological test 
scores (for example Moss et al., 2003; Locke et al., 2008; Victor et al., 2009), 
establishing this finding in an NHS sample would further support the relevance of 
performance validity testing in UK clinical settings as an empirical means of 
assessing the validity of test data.  
Hypotheses 
   It is hypothesised that a proportion of this NHS sample will fail multiple 
PVTs (including embedded and stand-alone measures). It is likely that this base rate 
will fall below 20%, as previous research in clinical, non-litigating populations 
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(Locke et al., 2008; Bunnage et al., 2008; Hampson et al., 2014) has looked at the 
prevalence of failure on individual PVTs as opposed to failure on multiple measures, 
which is a more conservative threshold.  Given the evidence from existing studies 
applying this criterion, a base rate of around 10 to 15% might be anticipated. Base 
rates of failure on single PVTs in this sample will be provided for comparison. 
   It is further hypothesised that groups categorised on the basis of passing or 
failing PVTs will differ in terms of their performance on cognitive tests. Based on 
previous research (Moss et al., 2003; Locke et al., 2008; Victor et al., 2009; Fox, 
2011), it is anticipated that the ‘fail’ group will exhibit reduced test scores in 
comparison to the ‘pass’ group. Performance will be compared on primary WAIS 
indices (Wechsler, 2008) IQ to explore difference in general intellectual functioning. 
Scores on additional battery measures such as Stroop Test (Golden, 1978), Verbal 
Fluency (from the Delis-Kaplan Executive Function System; Delis, Kaplan & 
Kramer, 2001) and Modified Card Sorting Test (Nelson, 1976) will be compared 
where these measures have been included as part of the flexible clinical assessment 
battery. It is hypothesised that the groups will not differ significantly on any 
demographic variables such as age, years of education, gender and injury severity. 
 
Method 
Settings  
   This study was approved by the London City and East NHS Research 
Ethics Committee and the local Research and Development Departments within the 
hosting NHS trusts (see Appendix 2). Data were gathered within two trusts, one in 
South London and the other in East London, both socioeconomically diverse areas 
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which was reflected in the patient population. The data were derived from three 
services to which the neuropsychology departments provide input and assessment: an 
inpatient neurorehabilitation unit; a community neurorehabilitation team and an 
outpatient service providing multidisciplinary neuropsychological assessment. Data 
from the first two services was gathered prospectively: all patients completed a 
‘flexible’ battery of cognitive tests (where measures are selected to explore specific 
hypotheses rather than determined a priori; Bauer, 2014) with the inclusion of PVTs 
if not planned as part of the assessment. Data from the third service was 
retrospectively gathered from patient archives. All patients attending this latter 
service were tested using a standard (fixed) battery of neuropsychological measures, 
unless their presentation precluded the administration of specific tests. The data were 
anonymised on-site and patient details were not identifiable to the researcher. The 
archival data was shared with a fellow Trainee Clinical Psychologist who assisted 
with the completion of the database (see Appendix 1 for details). All analyses and 
write-up were conducted separately.  
Participants 
   This study aimed to capture a patient sample which was representative of 
those accessing UK NHS adult neuropsychology services. As such, the inclusion 
criteria were kept purposefully broad to reflect the diversity of this population and 
consequently enhance the external validity of the study. All had a diagnosis of 
acquired brain injury corroborated by neurology reports, however, no parameters 
were set regarding type of injury or time since injury. 
   Patients were all over 18 years of age. Individuals with co-morbid mental or 
physical disorders were included where these disorders were not deemed to exert a 
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significant influence on testing (for example, individuals with acute psychiatric 
illness or visual impairment that would have precluded cognitive assessment were 
not included). A confirmed prior diagnosis of intellectual disability, degenerative 
neurological conditions (such as dementia or movement disorders) or functional 
neurological symptoms (such as conversion disorder) were used as a basis for 
exclusion from the study as these groups have been shown to score below cut-off 
more frequently on performance validity measures (Boone & Lu, 1999; Dean, 
Victor, Boone, & Arnold, 2008; Holdnack, Schoenberg, Lange, & Iverson, 2013; 
Davis & Millis, 2014; Meyers & Volbrecht, 2003). Patients who lacked capacity to 
consent to participation in the study (as assessed by their treating clinician) were also 
excluded. 
   Patients with identified external incentives were included. In this context, 
‘external incentives’ encompassed a range of factors which might be relevant in UK 
clinical settings, such as disclosure of ongoing medicolegal proceedings or receipt of 
state benefit. Although it is acknowledged that the presence of external incentives is 
an important moderating factor in PVT performance (Belanger et al., 2005), it is 
likely that, given the service context, the majority of patients would be ‘incentivised’ 
to some degree. For example, most would be eligible to claim some form of 
government allowance (for example, free prescriptions or Disability Living 
Allowance), and all would be potential candidates for ongoing input from services. 
Excluding participants on the basis of identifiable incentive would therefore 
substantially reduce the applicability of the findings in clinical practice. The presence 
of external incentives was assessed via direct questioning of the client, examination 
of medical notes and / or confirmation with the individual’s treating team.  
Power analysis 
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   Previous studies have investigated PVT failure in non-litigating samples on 
single (Locke et al., 2008; Bunnage et al., 2008; Hampson et al., 2014) and multiple 
measures (Meyers & Volbrecht, 2003; Kemp et al., 2008; Victor et al., 2009; Davis 
& Millis, 2014; Hall et al., 2014). For the base rate analysis it was assumed that the 
larger the sample, the greater the level of confidence in the base rate data. Power 
analysis for the group comparison was informed by prior work by Locke and 
colleagues (2008) based on available data from US non-litigating, treatment-seeking, 
acquired brain injury patients comparing TOMM pass and fail groups on tests of 
neuropsychological functioning. These authors found an average effect size of 0.98 
(large effect; Cohen, 1992) for comparisons across tests in a neuropsychological 
battery (including WAIS-III, WMS-III, Stroop, Category Fluency and Wisconsin 
Card Sort Test). On the basis of this, power calculation was carried out using the 
“G*Power 3” computer program (Faul, Erdfelder, Lang, & Buchner, 2007), 
specifying alpha at 5% and desired power at 80%. The allocation ratio for 
participants in Group 1 (pass) versus Group 2 (fail) was set to 0.18 to account for a 
15% estimated base rate of failure (i.e. N Group 1 = 85 / N Group 2 = 15). The 
required total sample size to detect significant group differences was estimated at 52 
(Group 1 = 44, Group 2 = 8), which was felt to be within the resources of the current 
investigation. A study with this sample size would represent a valuable contribution 
to the field: a previous publication utilising different measures with a similar NHS 
population had comparable sample size of 47 participants (Hampson et al., 2014). 
Recruitment procedure 
   Participants recruited prospectively were identified and approached to take 
part in the study by their treating clinicians. All participants had neuropsychological 
assessment planned as part of their clinical care. They were given the study 
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information sheet (see Appendix 3) at the time of their initial clinical interview 
(typically one week prior to the testing session) and then provided written consent 
(see Appendix 4) for their clinical data to be used for research prior to beginning 
cognitive testing. No incentives were provided to any of the participants. Assessment 
then took place as planned by the treating clinician, with the addition of PVTs if not 
already planned as part of the test battery. Written and oral feedback of test results 
was given to all patients as per usual service protocol. Demographic data from 
clinical interviews and medical records was also collected to provide information on 
age, gender, brain injury aetiology, time since injury, employment status and 
presence of external incentives.  
Measures 
   All participants underwent comprehensive cognitive assessment which was 
sufficient to support clinical formulation (Suesse et al., 2015). As this was a 
naturalistic study, the cognitive test data gathered varied between participants. The 
measures chosen for analysis therefore reflect those which were available for the 
patients in this data set. 
Performance validity measures 
   All participants completed the Test of Memory Malingering (TOMM; 
Tombaugh, 1996). Half of the participants also had data for an additional embedded 
PVT – the Digit Span Age-Corrected Scaled Score (DS-SS) or the Reliable Digit 
Span (RDS; Greiffenstein et al., 1994), both derived from the Wechsler Adult 
Intelligence Scale Digit Span subtest (Wechsler 1997; 2008). Digit span indices were 
selected as a) Digit Span was administered as standard to the majority of participants 
as part of the clinical assessment and b) it is a verbal measure, which contrasts to the 
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TOMM (a visual memory measure) thus meeting the stipulation of a ‘multi-method, 
multi-test’ approach to performance validity testing as recommended by the BPS 
(McMillan et al., 2009).  
   The TOMM is a standalone PVT which takes the form of a forced-choice 
visual recognition memory test. There are three trials, however, conventionally a 
score of less than 45 on Trial 2 is thought to be indicative of invalid performance 
(Tombaugh, 1996). At this cut-off, it has been found to correctly classify greater than 
90% of neurologically impaired patients as ‘not malingering’ (traumatic brain injury, 
aphasia, cognitive impairment and dementia; Tombaugh, 1997), with a more recent 
review indicating a pooled sensitivity of 61% and specificity of 89% (Hall et al., 
2014). The Retention trial was not administered for any patients, as in clinical 
practice time pressures frequently mean that abbreviated test procedures are utilised 
where possible and appropriate.  
   The Reliable Digit Span (RDS) was originally derived from the Digit Span 
subtest of the Wechsler Adult Intelligence Scale – Revised (WAIS-R; Wechsler, 
1981): a measure of immediate memory span for auditory-verbal information 
(Iverson & Franzen, 1994).  RDS is the sum of the longest forwards and backwards 
spans where both trials are correctly completed (Greiffenstein, et al., 1994). It has 
subsequently been applied to the Digit Span subtests of the WAIS-III and WAIS-IV 
(Wechsler, 1997 and 2008). A meta-analytic review of RDS validation studies 
(Schroeder et al., 2012) indicated that, at a cut-off of less than or equal to six, the 
RDS had a sensitivity rate of between 30 and 35% but a specificity of over 90% in 
most clinical groups studied, including moderate to severe traumatic brain injury. At 
a cut-off of less than or equal to seven global sensitivity was improved (58%) but 
specificity dropped to less than 90% across clinical groups. Given that, in clinical 
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practice, convention is to maximise specificity to reduce risk of false positives 
(Greve & Bianchini, 2004), a cut-off of less than or equal to six will be used for the 
purposes of this study.  
   The DS-SS is also derived from the Digit Span subtest of the WAIS-IV 
(Wechsler, 2008). Determination of the DS-SS follows standard administration and 
scoring procedures as laid out in the WAIS-IV manual (Wechsler, 2008). A cut-off 
of less than or equal to six has previously been used as an indicator of potential 
invalid performance, with a specificity of over 90% demonstrated in a sample of 
mTBI patients (Spencer et al., 2013). A more conservative cut-off of less than or 
equal to five was associated with a 5% increase in specificity and a concomitant 10% 
decrease in sensitivity. Given the heterogeneity of injury severity likely to be present 
within this sample, the more conservative less than or equal to five criterion was 
chosen as a threshold for classification. The DS-SS is less commonly used as an 
embedded PVT than Reliable Digit Span (RDS; Greiffenstein, et al., 1994; McCarter 
et al., 2009), however, it has equivalent classification accuracy (Jasinski, Berry, 
Shandera, & Clark, 2011; Young, Sawyer, Roper, & Baughman, 2012). DS-SS was 
used as the embedded measure for the archival data as RDS scores were not 
available.   
Cognitive measures 
   To ascertain if there were differences on cognitive testing between 
individuals passing and failing PVTs, scores were gathered from the wider 
neuropsychological test battery. The primary measures used in the analysis were 
verbal and performance indices of the Wechsler Adult Intelligence Scale (WAIS), as 
these tests tap a number of cognitive skills to provide an estimate of global 
89	
	
intellectual functioning.  The WAIS-III (Wechsler, 1997) and WAIS-IV (Wechsler, 
2008) have been extensively standardised (WAIS-III n = 2,450; WAIS-IV n = 2,200) 
and shown to have high reliability.  The majority of patients in the current sample 
had completed all subtests of the WAIS allowing for calculation of primaryindices 
and Full Scale IQ. Where shorter forms of the battery were utilised (for example, due 
to patient fatigue or time constraints), indices were pro-rated where possible as per 
the WAIS manual. Research has shown that even a two-subtest short form using only 
Vocabulary and Block Design produces good correlations with the Full Scale IQ of 
between 0.88 and 0.89, with longer short forms improving classification rates 
(Strauss, Sherman & Spreen, 2006, pp. 285-286).  
   Additional measures administered as part of the larger battery of tests 
included: Wechsler Memory Scale-IV Auditory and Verbal Memory (WMS-IV; 
Wechsler, 2009), Wechsler Memory Scale-III Verbal Working Memory, Immediate 
Memory (auditory and visual), Delayed Memory (auditory and visual) (WMS-III; 
Wechsler, 1997), Verbal Fluency (Delis, Kaplan, & Kramer, 2001), Modified Card 
Sorting Test (Nelson, 1976) and the Graded Naming Test (McKenna & Warrington, 
1983).  
Sample characterisation measures 
   Information on estimated premorbid functioning was gathered as part of 
sample characterisation. Both the Wechsler Test of Adult Reading (WTAR; 
Wechsler, 2001) and the Test of Premorbid Functioning (TOPF; Wechsler 2011) 
were used in this sample, as the TOPF superseded the WTAR following the 
publication of the WAIS-IV (the TOPF being co-normed with WAIS-IV, and WTAR 
with the WAIS-III; Brooks et al., 2011, p. 226). Both measures utilise an oral reading 
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paradigm that presumes the pronunciation of irregular words is relatively unaffected 
by neurological change (Brooks et al., 2011). They thus are statistical tools designed 
to assist determination of whether an individual’s current test performance represents 
a decline from their previous level of ability (Whipple Drozdick, Holdnack, Weiss & 
Zhou, 2013. p 67). Information on affective status was also included in the sample 
characterisation. The majority of patients had completed the Personality Assessment 
Inventory (PAI) self-report measure, which includes clinical scales for anxious and 
depressive symptomatology (Morey, 1991; 2007).  
Practical issues with the use of archival data  
   Different versions of tests were administered to patients before and after 
November 2011 (for example, WAIS-III versus WAIS-IV; WTAR versus TOPF), 
reflecting the availability of the most up-to-date test materials within the services. 
For the purposes of this study, full-scale IQ scores were analysed together across the 
different versions of the test. The potential lack of equivalence between the tests is 
acknowledged, as tests are refined over time to reflect updated conceptualisations of 
intelligence and re-standardised using new normative samples (Taub & Benson, 
2013). There is also the issue of the Flynn Effect (the observed rise in IQ scores over 
time), which may mean that individuals tested later on older test versions have 
artificially inflated scores, as they are being compared to older norms (Flynn, 1984; 
Trahan, Stuebing, Fletcher, & Hiscock, 2014). Given that a) this analysis did not 
seek to compare between WAIS-III and WAIS-IV scores, and b) that versions have 
been shown to measure similar constructs (Taub & Benson, 2013) and have strong 
correlations between FSIQ indices (r=0.94; Holdnack, Schoenberg, Lange, & 
Iverson, 2013, p 218), the data were collapsed across groups but this was accepted as 
a potential limitation of the study. 
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Data analysis 
A primary aim of this study was to provide information on the base rate of 
PVT failure in a naturalistic NHS clinical sample. The base rate (BR) of a condition 
of interest (in this case, below cut-off – or ‘failed’ - performance on PVTs) was 
calculated using the formula BR = number of cases with condition of interest / 
number of cases in the population (Gouvier, 1999). BRs were calculated for a) failure 
on the TOMM (as the most commonly-used standalone PVT), b) failure on any one 
PVT (TOMM or embedded PVT) and c) failure on two PVTs (TOMM and 
embedded PVTs). Pass and fail groups were analysed using SPSS 24 for Windows to 
examine differences in key demographic variables and current cognitive functioning, 
using WAIS Full Scale IQ as a measure of global ability. The PVT data had unequal 
sample sizes, hence non-parametric statistics were used throughout and a stringent 
criterion for significance was applied (p<.01).   
   As this is naturalistic patient data there is a significant degree of 
heterogeneity in the cognitive test scores available for each patient, as tests 
administered would be dependent on their presentation at assessment. The sample 
‘N’ for each analysis is therefore indicated to clarify where data is missing. Figure 1 
demonstrates how the final sample was derived from the prospectively gathered and 
archival data. 
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Figure 1: Participant flow through the study 
 
Notes: PVT = performance validity test; TOMM = Test of Memory Malingering 
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Results 
Sample demographics 
   A total of 144 sets of patient data were included in this study. This sample 
included males and females (66% male) with a broad range of acquired brain 
injuries. Traumatic brain injury accounted for 39% of the sample, other aetiologies 
included stroke / haemorrhage (35%), tumour (15%), infection / viral (2%), hypoxic 
injury (3%), epilepsy related (2%), encephalopathy (3%) and cysts (1%). Patients 
were a median 4 years post-injury, though there was a broad range (between 2 
months and 45 years 4 months). Information on length of post-traumatic amnesia, 
duration of loss of consciousness or Glasgow Coma Score was not consistently 
available, therefore it was not possible to categorise TBI patients based on injury 
severity.  
   The sample ranged in age between 18 and 74 years (M = 44, SD = 14). The 
average estimated premorbid IQ was close to the general population mean (M = 103, 
SD = 12). Information on identifiable external incentives was available for 97% of 
the total sample (139 patients): 20% of the sample were found to have identifiable 
incentives, which included medicolegal claims, access to welfare benefits (such as 
Disability Living Allowance [DLA], Employment Support Allowance [ESA] or 
Personal Independence Payments [PIP]) and those in pursuit of medical retirement. 
PVT performance: base rates 
   All patients (N = 144) completed the TOMM Trial 2. Fifteen patients 
scored below threshold on this measure (less than 45), giving a base rate of failure of 
10% (M = 48.1, SD = 5.57, range: 21–50). Five patients scored below chance and 
107 performed at ceiling.  Scores on a second, embedded PVT were only available 
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for approximately half of the sample (n = 73). In this analysis, ‘embedded’ PVTs 
comprised either the DS-SS or RDS (with a cut-off of less than or equal to five for 
the DS-SS and less than or equal to six for RDS) subject to which measure was 
available for each patient. Of those who had data available for two PVTs, 15 patients 
scored below threshold on at least one (21%). Nine of these 15 patients failed on an 
embedded measure. Three patients failed two PVTs (4%). A summary of this 
information is provided in Table 1.  
   An exploratory analysis using a less-conservative cut-off of less than or 
equal to six on the DS-SS was also conducted, given previous research citing this as 
an appropriate threshold for the appraisal of performance validity in brain-injured 
populations (Spencer et al, 2013). Using this threshold, there was a base rate of 26% 
failure on one or more PVTs. Six patients failed two PVTs with the use of this cut-
off (8%). Given the heterogeneity of this sample, and unknown severity of injury for 
the majority of patients, use of the less than or equal to five cut-off was deemed more 
appropriate for this analysis to reduce the likelihood of false positive errors.  
 
Table 1: Base rates of below cut-off performance on PVTs 
PVT variable  Sample N Number of 
fails 
Base rate of 
failure 
Failed TOMM only 144 15 10% 
Failed embedded PVT only 73 9 12% 
Failed ≥1 PVT  73 15 21% 
Failed 2 PVT 73 3 4% 
Note: PVT = performance validity test; TOMM = Test of Memory Malingering 
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Demographic comparisons between PVT pass and fail groups 
   PVT pass and fail groups were compared to ascertain if there were any pre-
existing demographic differences which may contribute to below-threshold 
performance.    Analyses were conducted across two variables of interest: 1) 
individuals who passed or failed the TOMM only; 2) individuals who failed on one 
or more PVTs compared to those passing all PVTs. The two PVT fail group was not 
analysed separately due to the small sample size, however, further qualitative 
characterisation of this group is provided below to supplement this analysis (see 
below).  
  Non-parametric tests were used to account for uneven group size (chi 
squared test for categorical variables; Mann-Whitney U test for continuous variables) 
and a stringent criterion for significance was applied (p<.01).  Demographic 
comparisons between the pass and fail groups indicated no significant differences in 
gender, age, time from injury to assessment, external incentives, employment status, 
estimated premorbid IQ and affective status (depression or anxiety). This information 
is summarised in Table 2. 
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Table 2: PVT pass and fail groups: demographic comparisons  
Notes: Median (range) scores are provided; **p<.01; ax = assessment; FSIQ = Full Scale IQ; PAI anx = Personality Assessment Inventory, anxiety subscale; PAI dep = Personality 
Assessment Inventory, depression subscale. Median and range scores are provided for the FSIQ and PAI variables. PAI T scores: <60 = no difficulty; 60-69 = mild to moderate 
difficulty; 70-82 = moderate difficulty; >82 = significant difficulty
 TOMM   ≥1 PVT 
Variable N Pass 
group n 
Fail 
group n 
Pass  Fail  p N Pass 
group n 
Fail 
group n 
Pass  Fail  p 
Gender 144  129 15 68% male 47% male 0.168 73 58 15 64% male 47% male 0.362 
Age (years) 144 129 15 44 (18-74) 38 (27-65) 0.509 73 58 15 46.5 (21-74) 44 (27-65) 0.306 
Time injury to 
ax (months) 
140 126 14 13 (2-545) 35 (1-340) 0.025 72 57 15 9 (2-545) 23 (4-340) 0.031 
External 
incentive 
138 124 14 19% yes 29% yes 0.644 72 57 15 16% yes 20% yes 1.000 
Employment 127 112 15 30% yes 27% yes 1.000 57 44 13 27% yes 23% yes 0.986 
Estimated 
premorbid FSIQ  
133 119 14 104 (64-132) 100 (63-115) 0.100 70 57 13 105 (64-132) 99 (63-121) 0.061 
PAI anx 123 111 12 56 (8-93) 67.5 (37-86) 0.061 53 44 9 51.5 (8-81) 63 (37-81) 0.362 
PAI dep 123 111 12 61 (5-105) 82 (32-95) 0.078 53 44 9 59 (5-101) 68 (32-98) 0.129 
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Of note is that, although comparisons did not reach the threshold for 
significance, those failing PVTs had a consistently longer median duration between 
injury and the assessment (suggesting greater chronicity of brain injury-related 
difficulties) and scored higher on measures of affective status (suggesting a greater 
degree of symptomatology). Regarding affective status, individuals failing the 
TOMM were the only group to have median depressive symptom scores in the range 
for ‘significant difficulty’ as per the PAI scoring system (Morey, 1991; 2007). Scores 
across the groups for depression and anxiety were otherwise all in the mild to 
moderate range. Median premorbid FSIQ estimates of all groups fell within the 
‘Average’ range as per the standard WAIS descriptors (Wechsler, 2008), with the 
full range of ability represented (range: 63 – 132). 
PVT pass and fail groups: current cognitive functioning 
   Consistent with the second goal of this study, neuropsychological test 
results were compared between pass and fail groups across the variables of interest 
identified above. Median scores for WAIS-IV (FSIQ), Verbal Comprehension Index 
(VCI) and Perceptual Reasoning Index (PRI) are reported in Table 3 as primary 
measures of current cognitive function. Mann-Whitney U tests revealed that 
individuals failing PVTs (whether this was one or two fails) performed consistently 
worse on these measures than their counterparts who passed PVTs. As indicated in 
Table 3, the majority of analyses were significant at the p<.01 level. The differences 
in FSIQ between those passing all PVTs and those failing one or more PVTs 
remained significant at p<.001, with a large effect size noted (U = 74, z = -4.04, r = -
0.53).
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Table 3: Comparison of median scores on primary cognitive measures across PVT groups 
 
Notes: *p<.05, **p<.01, ***p<.001; FSIQ = WAIS Full-scale IQ; VIQ/VCI = WAIS Verbal IQ/Verbal Comprehension Index; PIQ/PRI = WAIS Performance 
IQ/Perceptual Reasoning Index. 
 
 
 
 
 TOMM ≥1 PVT 
Variable N Pass 
group n 
Fail 
group n 
Pass group 
median 
score 
Fail group 
median 
score 
p r N Pass 
group n 
Fail 
group n 
Pass group 
median 
score 
Fail group 
median 
score 
p r 
FSIQ 119 105 14 97 89 0.005** -0.26 57 44 13 97 71 <.001*** -0.53 
VIQ/VCI 67 59 8 98 73 0.030* -0.26 61 48 13 101 91 0.001** -0.41 
PIQ/PRI 75 67 8 98 78 0.001** -0.37 67 53 14 102 82.5 0.001** -0.40 
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   To further explore differences in overall cognitive functioning between 
individuals failing 0, 1 or 2 PVTs, FSIQ scores were compared between the three 
groups. A Kruskal-Wallis Test revealed a statistically significant difference across 
the three groups (0 fail, n = 44; 1 fail, n = 10; 2 fails, n = 3; chi-square [2, 57] = 17.9, 
p<.001). Post-hoc testing to explore significant comparisons indicated that the FSIQ 
score of the 0 fail group (Md = 97) was significantly higher than that of both the 1 
fail (Md = 80.5, U = 74, z = -3.25, p = 0.001, r = -0.44) and 2 fails (Md = 51, U = 
.000, z = -2.88, p = 0.004, r = -0.42). The 1 and 2 fail groups were significantly 
different at the p<.05 level (U = .000, z = -2.54, p = .011). These results imply that 
the strong effect sizes for the ≥1 PVT fail group demonstrated in the FSIQ 
comparison above are not driven purely by the presence of ‘2 PVT fail’ individuals 
within that group, but that the failure of a single PVT alone is associated with 
significantly poorer scores on cognitive testing than if all PVTs are passed.  
   Examination of the median FSIQ scores for each group would suggest that 
failing more PVTs is associated with decreasing global cognitive ability. Although 
data from the ‘2 PVT fail’ group should be viewed as exploratory due to small 
sample sizes, all patients in this group had lower scores on this measure than the 
lowest-scoring patients in the ‘0 fail’ and ‘1 fail’ groups, with scores falling into the 
‘Extremely Low’ range (that is, lower than 98% of the general population). Only two 
of the three patients in this group had premorbid IQ estimates available, however, 
both fell in the ‘Average’ range (102 and 92), suggesting that they did not have low 
baseline FSIQ scores relative to others in the sample which might account for the 
findings. For comparison, the median FSIQ score of the ‘1 fail’ group fell within the 
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‘Low Average’ range (Md = 80.5, range = 68-96), compared to estimated premorbid 
scores also in the ‘Average’ range (Md = 99, range: 63–121).  
Comparing pass and fail groups on performance in specific cognitive domains 
   To explore whether PVT failure was associated with reduced performance 
in specific cognitive domains, comparisons were made between those individuals 
passing all PVTs and those failing one or more PVTs across a battery of 
neuropsychological tests. Data were missing for some variables, however, the 
minimum total n was 47 patients (minimum fail group n = 8). Failure on one or more 
PVTs was strongly associated with lower scores across the Working Memory, 
Processing Speed and General Ability indices of the WAIS-IV; the Verbal Working 
Memory and Visual Recognition subscales of the WMS-III; Category Fluency, the 
Graded Naming Test and Stroop test (see Table 4).   
The analysis was repeated for individuals passing and failing the TOMM only 
(see Table 5). Due to variations in test batteries between patients there were fewer 
neuropsychological measures consistently available for comparison, however, there 
were larger sample sizes: total n’s ranged from 98 (Stroop) to 121 (WAIS PSI), with 
fail group n’s ranging from 10 (MCST) to 14 (WAIS indices). Results echoed the 
previous analysis: TOMM pass / fail groups differed significantly on all WAIS 
indices bar VCI, on the GNT and on the Stroop. Effect sizes, however, were all small 
to medium as opposed to medium to large.
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Table 4: Cognitive test scores for individuals passing and failing ≥1 PVT   
Test variable N Pass 
group n 
Fail 
group n 
Pass 
Md (range) 
Fail 
Md (range) 
p r  
WAIS-IV         
    WMI 56 43 13 97 (74-135) 77 (60-100) <.001*** -0.54  
    PSI 55 43 12 92 (65-146) 72.5 (50-94) <.001*** -0.50  
    GAI 56 43 13 101 (69-144) 81 (52-105) <.001*** -0.48  
WMS-IV         
    AM 53 43 10 97 (51-124) 84.5 (55-110) .232 -0.16  
    VM 52 43 9 92 (63-138) 85 (76-87) .013* -0.34  
WMS-III           
    VWM 52 42 10 89.5 (69-126) 75 (63-88) .001** -0.46  
    IM 52 43 9 96 (65-129) 81 (61-98) .086 -0.24  
    DM 51 42 9 92 (56-130) 82 (62-100) .092 -0.24  
    AI 51 41 10 94 (42-123) 86 (56-108) .301 -0.14  
    AD 51 41 10 92 (48-127) 83 (52-144) .454 -0.10  
    AR 51 41 10 91 (45-118) 85.5 (49-98) .058 -0.27  
    VI 47 38 9 92 (50-127) 80 (74-92) .056 -0.28  
    VD 47 38 9 92 (63-140) 85 (75-95) .085 -0.25  
    VR 46 37 9 90 (57-120) 80 (72-87) .008* -0.39  
FAS         
    Letter 53 43 10 8 (1-19) 6.5 (3-13) .218 -0.17  
    Category 53 43 10 9 (2-16) 6 (1-10) .001** -0.46  
    Switch correct 53 43 10 9 (1-15) 7 (1-12) .059 -0.26  
    Switch accuracy 53 43 10 10 (1-31) 8.5 (2-11) .069 -0.25  
MCST         
   Categories 49 42 7 6 (1-6) 5 (1-6) .135 -0.21  
   % perseverative 
errors 
49 42 7 27.5 (0-100) 40 (33-68) .169 -0.20  
 GNT (raw) 51 41 10 21 (1-28) 7 (4-17) <.001*** -0.50  
 Stroop (raw) 40 29 11 85 (10-112) 
 
70 (17-93) .028* -0.37  
Notes: *p<.05, **p<.01, ***p<.001. WAIS-IV = Wechsler Adult Intelligence Test-IV (Wechsler, 
2008); WMI = Working Memory Index; PSI = Processing Speed Index; GAI = General Ability Index; 
WMS-IV = Wechsler Memory Scale-IV (Wechsler, 2009); AM = Auditory Memory Index; VM = 
Verbal Memory Index; WMS-III = Wechsler Memory Scale-III (Weschler, 1997b); VWM = Verbal 
Working Memory; IM = Immediate Memory; DM = Delayed Memory; AI = Auditory Immediate; AD 
= Auditory Delayed; AR = Auditory Recognition; VI = Visual Immediate; VD = Visual Delayed; VR 
= Visual Recognition; FAS = DKEFS verbal fluency test (Delis, Kaplan, & Kramer, 2001); MCST = 
Modified Card Sorting Test (Nelson, 1976); GNT = Graded Naming Test (McKenna & Warrington, 
1983).  
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Table 5: Cognitive test scores for individuals passing and failing the TOMM only 
Test variable N Pass 
group n 
Fail 
group n 
Pass group 
Md (range) 
Fail group 
Md (range) 
p r 
WAIS-III / IV        
    PSI 121 107 14 89.5 (56-146) 79 (50-144) .002** -0.29 
    WMI 120 106 14 97 (63-144) 87.5 (60-119) .039* -0.19 
MCST        
   Categories 108 98 10 6 (1-6) 5 (3-6) .315 -0.1 
   % perseverative errors 108 98 10 22.5 (0-100) 21 (0-68) .977 -0.002 
 GNT (raw) 108 96 12 20.5 (1-29) 15 (4-24) .03* -0.21 
 Stroop (raw) 
 
98 87 11 87 (9-112) 66 (17-96) .012* -0.25 
        
Note: *p<.05, **p<.01, ***p<.001. WAIS-III/IV = Wechsler Adult Intelligence Scale-III/IV (Wechsler, 
1997b; 2008); WMI = Working Memory Index; PSI = Processing Speed Index; MCST = Modified Card 
Sorting Test (Nelson, 1976); GNT = Graded Naming Test (McKenna & Warrington, 1983); Stroop = 
Stroop Test (Golden, 1978). 
 
 
Clinical characterisation of patients failing two PVTs 
   Qualitative analysis of the demographics and neuropsychological test 
performance of the three patients failing two PVTs was conducted to characterise the 
group and ascertain if there were clinical features which may have influenced 
performance.  
   Patient A had a diagnosis of severe TBI eight months prior to the 
assessment. Co-morbid depression was reported. An atypical pattern of dense 
retrograde amnesia was observed on self-report. On testing it was noted that auditory 
and visual recognition scores on the WMS were reduced in comparison to auditory 
and visual delayed free-recall (delayed scores both in Low Average range), which 
again is atypical. No premorbid IQ estimates were available, however, current 
intellectual functioning fell in the Extremely Low range (WAIS-IV FSIQ standard 
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score = 51, score exceeding less than 0.1% of peers). This patient was in the process 
of applying for DLA at the time of assessment. TOMM Trial 2 score was 38; DS-SS 
was 3. 
   Patient B had experienced a moderate TBI due to assault three years prior 
to the assessment. It was noted that the assessment was challenging due to low 
confidence on testing and the fact that English was a second language; as such the 
majority of the battery was not completed. A number of significant social welfare 
issues were reported. Estimated premorbid IQ was estimated to be in the average 
range. Current intellectual functioning was found to be in the Extremely Low range 
(WAIS-IV FSIQ standard score = 49, score exceeding less than 0.1% of peers). 
TOMM Trial 2 score was 27; DS-SS was 2. 
   Patient C had undergone neurosurgery to remove a brain tumour in 
childhood and subsequently developed cognitive difficulties and epilepsy. Co-morbid 
psychiatric symptomatology was present which likely impacted engagement on 
tasks. An ‘apathetic’ approach to testing was observed. Premorbid IQ estimates were 
in the average range, current intellectual functioning was in the Extremely Low range 
(WAIS-IV FSIQ standard score = 65, score exceeding less than 1% of peers). No 
external incentives were noted. TOMM Trial 2 score was 41; DS-SS was 4. 
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Discussion 
   This study aimed to establish the base rate of PVT failure in a post-acute 
NHS acquired brain injury sample, in addition to understanding whether failing 
PVTs was associated with reduced scores on cognitive assessment. Limited data 
exist regarding the performance of NHS patient samples on PVTs, despite 
professional bodies recommending that they be used routinely in clinical evaluations 
(McMillan et al., 2009). As such, garnering data from clinical settings is essential to 
increase understanding in this area and thus assist clinicians to make more accurate 
judgements regarding the nature of individual deficits.  
Base rates of PVT failure 
   In this sample, there was a base rate of 10% failure on the TOMM; 21% 
failure on at least one PVT when two were administered (the TOMM plus one Digit 
Span-derived embedded PVT) and 4% failure on two PVTs. To the author’s 
knowledge, this is the first UK clinical study of this size to establish base rates of 
failure on these measures. Previous research from the US using a comparable clinical 
sample found a base rate of 22% failure on the TOMM (Locke et al., 2008). The 
finding of only 4% of the sample failing two PVTs as per the ‘multi-method, multi-
test’ approach advocated by professional practice guidelines (McMillan et al., 2009; 
Heilbronner et al., 2009) is lower than originally hypothesised. It is similar to Victor 
et al.’s (2009) results demonstrating a 6% base rate in ‘credible’ patients, but 
substantially less than other studies using non-litigating clinical samples  (for 
example, 15% in Davis & Millis, 2014), including studies conducted in the UK (for 
example, 11% in Kemp et al., 2008).  
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The relationship between PVT failure and neuropsychological test performance 
   Where individuals with confirmed brain injury failed one or more PVTs, 
they were more likely to have lower scores on global measures of current cognitive 
functioning than those passing PVTs. This was also the case on specific tests tapping 
verbal working memory, visual memory, semantic fluency, object naming and 
processing speed. This effect was found in the context of pass and fail groups being 
broadly matched on all other demographic variables including estimated premorbid 
IQ. Effect sizes for the significant comparisons were moderate to large (as per 
Cohen, 1992), indicating that these group differences would be substantial enough so 
as to be clinically distinguishable (Bigler, 2014).  
   The use of PVTs is predicated on the assumption that ‘passing’ the tests 
places such negligible demands on cognition that they can be considered impervious 
to all but the most severe forms of central nervous system dysfunction. They are 
therefore purported to provide clinicians with additional information on non-
neurological dimensions of performance. If this were the case, one might anticipate 
that performing below published cut-offs on these measures would lead to a pattern 
of generally compromised scores across the neuropsychological test battery, as any 
superordinate factors would presumably impact on all measures to some degree. The 
findings of this study suggest that group differences between people passing and 
failing PVTs do not occur in a uniform pattern across test batteries but appear to 
differentially impact specific tests. As such, an alternative hypothesis may be that 
PVTs are picking up on aspects of individual organic deficit in addition to – or 
perhaps instead of - the ‘non-neurological’ factors they were designed to assess. 
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   The evidence-base is equivocal on the matter of whether PVT-predicted 
downgrading of neuropsychological performance can be related to individual 
cognitive impairment. The results of the current study echo those demonstrated by 
Locke et al. (2008), where inconsistent performance across a neuropsychological 
battery was also demonstrated in individuals passing and failing the TOMM. The 
authors hypothesised that this effect was, however, unlikely to be secondary to 
organic factors as failure rates were unrelated to proximal variables of cognitive 
impairment severity (such as injury severity, employment status and disability 
status). Conversely, studies investigating other forced-choice PVTs in clinical 
samples (Hall et al., 2014, Keary et al., 2013) have attributed poor performance of 
‘fail’ groups to the cognitive demands of the PVT (for example verbal processing 
and working memory for the Word Memory Test and Victoria Symptom Validity 
Test respectively), which would imply a primary influence of organic factors. In the 
dementia literature, decreasing cognitive functioning has been correlated with poorer 
performance on the TOMM, which one study found to be one of the PVTs most 
sensitive to the severity of cognitive impairment (Rudman, Oyebode, Jones, & 
Bentham, 2011).  
   In cognitive neuroscience, functional Magnetic Resonance Imaging (fMRI) 
research has shown that any task over and above primary sensory stimulation will 
require ‘effort’ and therefore will engage cognitive processes, regardless of how 
trivial the task may objectively appear (see Bigler, 2014, for a review). Given the 
nature of the PVTs used in this study, one could assume that a degree of attentional 
and working memory capability would be required to attempt them. It has been 
established that the frontotemporal and limbic regions thought to underpin these 
functions have the greatest propensity for damage in TBI (Cowell, Bussey & 
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Saksida, 2006; Allen, Bigler, Larsen, Goodrich-Hunsaker, & Hopkins, 2007; West, 
Curtis, Greve, & Bianchini, 2010), which potentially lends further credence to the 
‘organic cause for PVT failure’ hypothesis. Further research is needed, however, to 
establish a) whether performance on different PVTs varies with condition or lesion 
location and b) if it is possible to clearly delineate which neuropsychological 
measures are likely to be suppressed in relation to different PVTs.  
   With respect to point (b), the results of this study would suggest that failing 
the TOMM or Digit Span-derived PVTs is not associated with worse performance on 
the Modified Card Sorting Test (MCST; Nelson, 1976) or phonemic fluency 
(DKEFS; Delis, Kaplan, & Kramer, 2001), both of which are considered tests of 
higher-level executive functions which are sensitive to brain injury. Similarly, the 
two measures on which group differences were not demonstrated in the Locke et al. 
(2008) paper were the Wisconsin Card Sort Test (WCST; Grant & Berg, 1948; 
Heaton, 1981; Heaton, Chelune, Talley, Kay, & Curtiss, 1993) and the Category Test 
(Russell & Levy, 1987), which are again executive measures assessing complex 
skills such as concept formation, abstraction and cognitive flexibility. Examination 
of the median MCST scores in the current study (see Table 4) indicate that 
individuals in the pass group are performing overall in the average range (greater 
than the 45th per centile for categories; 25th-30th per centile for perseverative errors) 
compared to the low average to average range for the fail group (35th – 40th per 
centile for categories; 10th-15th for perseverative errors; norms from Obonsawin et 
al., 1999). One would anticipate that tests exerting greater demands on executive 
functions would be among those most vulnerable to both brain injury and any non-
neurological factors influencing performance, but these data are not consistent with 
this. It is possible that, given small sample sizes for fail groups, this represents a 
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spurious finding: further research is therefore needed to explore the associations of 
specific tests with PVT performance, specifically those assessing higher-level 
executive functions most commonly impaired in brain injury.  
Differences between the TOMM and embedded measures 
   The PVTs investigated in this study were chosen as together they met the 
demands of the ‘multi-test, multi-method’ approach advocated in professional 
guidelines for the use of PVTs (McMillan et al., 2009; Heilbronner et al., 2009). It 
was not a primary aim of the study to compare their relative utility, however, the data 
raised some pertinent issues related to their use in clinical populations. Firstly, larger 
effect sizes were demonstrated when the analyses combined Digit Span PVT and 
TOMM fails (the ‘one or more PVT fails’ group) than when TOMM fails were 
analysed separately (see Tables 4 and 5). This suggests that inclusion of Digit Span 
PVT fails strengthens the association between PVT failure and underperformance on 
specific neuropsychological tests. Given the arguments presented above, is it 
possible that Digit Span embedded PVTs are more likely to pick up on organic 
deficits than the TOMM? As highlighted by Bigler (2012), using embedded 
measures which were not explicitly designed to assess validity makes the issue of 
‘disentangling’ true neuropsychological deficits from associated non-neurological 
elements all the more complex. It seems parsimonious to infer that where brain 
injured individuals are vulnerable to disruption in neural networks underpinning the 
cognitive functions needed to do the Digit Span task (that is, auditory attention and 
working memory), performance will be suppressed on both the task and the PVT 
related to the task. Indeed, examination of median scores on the Working Memory 
Index (of which the Digit Span test is a primary subtest) indicated a 10 point 
difference in standard scores between people who failed any one PVT (Md = 77; 
109	
	
range: 60-100) versus those who just failed the TOMM (Md  = 87.5; range: 60-119). 
Even though cut-offs have been validated in brain injured populations (Spencer et al., 
2013), these results suggest that caution should be exercised when interpreting 
patient performance on embedded validity measures and supports the assertion that 
these indices should not be used in the absence of standalone PVTs (Miele et al., 
2012).  
Impact of the number of PVTs failed 
   Previous research has indicated that a criterion of two or more PVT fails 
should be used to indicate invalid performance (see Larrabee, 2014 for a discussion 
of this issue). The current study demonstrated that, in clinical practice, very few 
patients will fail two PVTs but a substantial minority will fail at least one. These 
results are consistent with the literature, and again underscore the need for caution 
when interpreting the output of PVTs in clinical settings. Whilst it is possible that 
individuals without cognitive deficits may achieve 100% specificity on PVTs, it is 
unlikely that bona fide patients with neurological conditions will perform at this 
level. The majority of PVTs were developed with medicolegal populations in mind, 
where the aim was to identify intentionally feigned symptoms. The tests have since 
been adopted by clinical practitioners as a means of identifying amplified symptoms 
in the context of established clinical syndrome, which is likely to place far greater 
demands on the instrument’s predictive validity (Merten et al., 2007). Clinicians 
must therefore adjust their conclusions accordingly whilst bearing in mind that 
within their pool of patients failing one PVT there will likely be a mix of true-valid 
and true-invalid performers (Martin et al., 2016). A number of authors assert that 
qualitative analysis of PVT fail scores is necessary to ameliorate this issue. Rigid 
application of cut-offs in clinical groups risks imposing artificial valid-invalid 
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dichotomies (Willis, Farrer, & Bigler, 2011), and it may be that considering 
individual performance on a spectrum from ‘likely valid’ to ‘likely invalid’ would be 
more appropriate. Of the 15 individuals in this study who performed below the 
published cut-off on the TOMM Trial 2, seven scored over 40. It is with this ‘near 
pass’ group that clinicians are at greatest risk of making false positive errors (Bigler, 
2012), and further guidance on whether cut-off scores should be variable depending 
on the characteristics of specific patient subgroups is therefore warranted. 
   By contrast, the evidence base suggests that individuals failing two or more 
PVTs likely constitute ‘true invalid’ test-takers, even in clinical groups (Larrabee, 
2014; Martin et al., 2016). Qualitative analysis of the three patients in the two-PVT 
fail group in this study brought to light a number of factors which may pose threats 
to valid performance. For example, developmental neurological compromise, co-
morbid psychiatric diagnosis, borderline IQ and English as a second language have 
all been linked to failure on PVTs (Salazar, Lu, Wen, & Boone, 2007; Dean et al., 
2008; Victor et al., 2009). In addition, two of the three were observed to have overt 
difficulties engaging with the assessment, and the third had an atypical amnestic 
presentation both in self report and on objective memory measures. Whilst it is not 
possible to discern from this limited information whether these represent ‘true 
invalid’ assessments, there appears to be reasonable convergence from PVTs, self-
reports, behavioural observations and patterns of neuropsychological scores to query 
if the assessment results are fully representative of individual cognitive ability. 
Methodological critiques and recommendations for future research 
   In the British Psychological Society (BPS) guidelines on the assessment of 
effort (McMillan et al., 2009), the need for further evidence on UK base rates of 
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cognitive impairment and PVT performance was identified. However, only a handful 
of studies have been published to meet this research goal (including Hall et al., 2013; 
Hampson et al., 2014; Suesse et al., 2015). This is the first study to investigate 
performance of a clinical acquired brain injury group on the TOMM, the PVT most 
commonly used in UK clinical neuropsychology practice (McCarter et al., 2009). 
The fact that this study has a comparatively large total sample size relative to 
previous studies in UK clinical populations (see Kemp et al., 2008; Hampson et al., 
2014 and Hall et al., 2014 which had samples of 43, 47 and 48 patients respectively) 
suggests that some confidence can be placed in the base rate data. The sample 
comprised participants with a wide range of neurological diagnoses of varied severity 
which are representative of the referrals received by NHS acquired brain injury 
services. No systematic biases in demographic variables were identified, which 
enhances the ecological validity of this research. Given these points, it is hoped that 
these data are strongly applicable to the day-to-day practice of NHS clinical 
psychologists and neuropsychologists.  
   There are, however, a number of potential limitations to this study. 
Methodologically, although the diagnostic heterogeneity represents a strength of this 
study, there was no available means of quantitatively comparing the severity of 
injury or condition across the groups. This would have been a beneficial addition to 
the analysis as an index of likely cognitive impairment, as the ‘dose-response’ 
relationship between injury severity and neuropsychological outcome has been 
previously established (Dikmen, Machamer, Winn, & Temkin, 1995). Qualitative 
comparison of diagnoses between the pass and fail ‘one or more’ PVT groups 
demonstrated similar proportions of TBI patients (28% versus 33%) but a greater 
proportion of CVA/stroke patients in the pass group (43%) and a greater proportion 
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of tumour patients in the fail group (40%). Specific analysis of how individuals with 
different diagnoses can be expected to perform on the TOMM and embedded PVTs 
would be valuable, however, the small sample sizes of subgroups in this analysis 
precluded this.  
   As a general critique, all analyses had uneven sample sizes and 
correspondingly some samples for fail groups were small: this is a challenge within 
the PVT research as a whole, and was offset in this study as far as possible by the use 
of non-parametric statistics and more conservative criteria for significance. 
Nonetheless, this is a caveat to bear in mind when interpreting the data from the 
group comparisons, which should be viewed as preliminary. 
   A further criticism rests with the choice of PVTs. The professional 
guidelines advocate a ‘multi-test, multi-method’ approach which is useful as, in 
practice, we do not know how expressions of invalid performance might manifest 
across the course of an assessment battery or over testing in different cognitive 
domains. However, guidelines do not specify which combinations of tests will 
provide the greatest degree of classification accuracy. The use of multiple measures 
will only provide additional benefit if the results of each classification are 
independent from each other (Rosenfeld et al., 2000). More research establishing the 
inter-correlations between PVTs is therefore necessary to clarify which combinations 
of tests offer the greatest classification accuracy in clinical populations. 
   Regarding the study sample, the inclusion of individuals with identified 
external incentives may be a criticism of this study. Approximately 20% of the 
sample were known to have identifiable incentives, some of which included 
medicolegal claims. It has previously been established that individuals with 
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incentives, and particularly those with ongoing litigation proceedings, are more 
likely to fail PVTs (Bianchini, Curtis, & Greve, 2006). For this reason, studies using 
clinical samples frequently exclude patients on the basis of identified incentives. The 
decision to include incentivised patients in this study was intentional as the aim was 
to characterise a typical population presenting to NHS brain injury services, which 
will inevitably include a proportion of individuals with incentives, and it is of note 
that the proportion of patients with identified incentives did not differ significantly 
between pass and fail groups. It is also recognised that categorising individuals on 
the basis of incentive is somewhat arbitrary, as the true extent that someone is 
incentivised to do well on an assessment is essentially unknowable. Many patients in 
this sample would, for example, be eligible for ongoing treatment. One could also 
consider a range of psychological mechanisms, both conscious and unconscious, 
which may function to ‘incentivise’ the patient to perform in a specific way, for 
example a desire to be validated for perceived difficulties, or as a ‘cry for help’ 
(Locke et al., 2008).   
   In relation to this, one of the central critiques of this study, and indeed of 
the literature as a whole, is the lack of clarity regarding the source of the PVT failure. 
Whilst there are a number of arguments which would link the PVT fails in this study 
to potential organic deficit, based on these data there is no way of precisely 
delineating the involvement of factors over and above cognitive impairment. Mood 
factors were not explored in this analysis, however, it is possible that psychological 
variables are an important source of variance in the neuropsychological test data.  
For instance, it is noteworthy that, whilst comparisons did not reach statistical 
significance, individuals failing the TOMM had higher self-reported depressive 
symptomatology than any other group (PAI depression scores in the ‘significant’ 
114	
	
range).  Studies have demonstrated that depressed patients who pass PVTs do not 
have suppressed scores on neuropsychological testing (Rohling, Green, Allen, & 
Iverson, 2001), but depressed patients who fail PVTs do demonstrate reduced scores 
on test batteries (Green et al., 2001). Thus there appears to be a meaningful 
interaction between depressive symptomatology and PVT failure which may provide 
a further context in which to understand the results of this study.   
  Concerning psychological variables, the questionnaire measures of trait 
anxiety and depression would not have identified test-related issues such as 
performance anxiety, which are more typically observed by examiners during testing. 
Working memory has been found to be down-regulated in anxiety (Ikeda, Iwanaga, 
& Seiwa, 1996; Robinson, Vytal, Cornwell, & Grillon, 2013), therefore there is an 
argument that reduced Digit Span scores, and by association the PVTs derived from 
them, may be a marker of in-the-moment affective state. One might query whether a 
degree of neurological compromise would also increase susceptibility to the impact 
of anxiety and lead to more pronounced underperformance (Waldstein, Ryan, 
Jennings, Muldoon, & Manuck, 1997), thus the pattern of results might be indicative 
of a combination of organic and psychological factors. The use of symptom self-
report measures with inbuilt validity scales (such as the Personality Assessment 
Inventory; Morey, 1991; 2007) alongside PVTs could go some way to detecting the 
influence of psychogenic variables on PVT performance and would therefore be a 
useful focus for future research. 
Clinical utility of the findings 
   This research highlights a number of practical and conceptual issues which 
are pertinent to clinical neuropsychological practice within NHS acquired brain 
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injury services. The study demonstrated that  a significant minority of individuals 
with established diagnoses of brain injury will fail the TOMM and/or Digit Span-
derived PVTs using established cut-offs, but only a very small percentage will fail 
two PVTs. This knowledge could be a useful heuristic in clinical practice even 
though the data cannot conclusively state the number of ‘true invalid’ performers 
identified. PVT failure could be viewed as a ‘red flag’ indicating that low scores on 
cognitive testing may not be directly attributable to a condition of the brain. 
However, assessments should not automatically be judged as ‘invalid’ on the basis of 
failed PVTs. Firstly, cognitive impairment could still be a potential explanation for 
PVT underperformance, and clinicians should examine whether there is convergent 
evidence of impairment on measures which tap cognitive domains overlapping with 
PVTs (for example visual recognition memory for the TOMM; verbal attention and 
working memory for the Digit Span measures) as this could indicate ‘risk factors’ for 
PVT failure.  With this in mind, the use of embedded Digit Span validity measures in 
isolation is not recommended in a clinical setting. Results of these measures should 
be interpreted with caution in acquired brain injury groups as the nature of their 
condition means they are vulnerable to working memory deficits. 
  Secondly, although PVT failure may reduce confidence in the objective 
findings of neuropsychological test data, it should serve to stimulate further enquiry 
into the clinical facts of the case. Little is known about the psychological 
mechanisms underpinning the experience of validity test failure on a group level, 
however, using PVT performance as part of the broader clinical formulation could 
guide a more nuanced understanding of the patient’s needs on a case-by-case basis.  
   This research has highlighted the challenges inherent in attempting to utilise 
PVTs in NHS clinical practice. Using PVTs will not enable clinicians to draw 
116	
	
definitive conclusions about performance validity, and indeed to do so would pose a 
significant risk of making false positive errors. There are a number of areas of 
research need which must be clarified before the clinical community can start 
applying PVTs and their associated cut-off scores with confidence. Until then, it is 
recommended that they are utilised with the aforementioned caveats in mind and 
always in the context of comprehensive assessment of potential biopsychosocial 
influences on performance.  
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In conducting this research I have encountered a number of conceptual issues 
which I feel speak strongly to the clinical applications of my findings. These are 
touched on briefly in the empirical paper, however, I believe that they warrant 
extended discussion here.  
Clinician attitudes to performance validity testing 
   All participants recruited prospectively into the study required 
comprehensive neuropsychological assessment as part of their clinical care, however, 
only a small minority of these had performance validity assessment planned as part 
of their clinical test battery. In fact, some clinicians reported informally that they 
would not have utilised standalone performance validity tests (PVTs) in most cases 
had they not been taking part in this research study. As such, one could conclude that 
performance validity testing was not considered an essential component to 
comprehensive assessment. Where the archival sample had more consistent testing 
with PVTs, this was primarily related to the long-standing research interests of the 
team. This anecdotal experience raises questions about the degree to which clinical 
guidelines regarding the use of PVTs are currently being followed. The British 
Psychological Society (BPS) professional guidelines on the assessment of effort in 
clinical settings were released in 2009 (McMillan et al., 2009), and stated 
unequivocally that PVTs should be given routinely as part of clinical assessment of 
cognitive function. As such, it was interesting to note that eight years on from the 
publication of this guidance there does not appear to have been a consistent shift in 
clinical practice at ground level. 
   These observations mirror the results of a 2009 survey of 130 practicing 
UK neuropsychologists by McCarter, Walton, Brooks & Powell (2009), which 
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indicated that only 16% of respondents routinely used PVTs in clinical assessments. 
Since 2009, the performance validity assessment field has expanded dramatically, to 
the extent that between 2011 and 2016, 25% of peer-reviewed articles published by 
The Clinical Neuropsychologist and Archives of Clinical Neuropsychology were 
related to this topic (Martin, Schroeder & Odland, 2015). Whilst it was outside the 
scope of this research project to examine the specific attitudes and beliefs of the 
clinicians involved towards performance validity testing, there have been a number 
of recently published articles which have explored this issue further.  
   In a large survey of neuropsychologists across six Western European 
countries (not including the UK), Dandachi-Fitzgerald, Ponds & Merten (2013) 
found inconsistencies between the acknowledgement of the occurrence of non-
credible symptoms in clinical practice (average clinician prevalence estimates were 
around 10%) and the use of objective measures to assess this phenomenon. Fifty per 
cent of the 492 clinical neuropsychologists surveyed reported that, despite having 
technical knowledge of performance validity, they ‘very rarely or never’ included 
PVTs in their assessments, opting to rely on qualitative metrics such as discrepancies 
between records, self-report and behaviour, or finding that the severity of cognitive 
impairment conflicted with known aspects of the patient’s condition. By contrast, 
two North American surveys (Martin et al., 2015; Schroeder, Martin & Odland, 
2016) found a pronounced “paradigm shift” in clinical neuropsychological practice 
in the years since the publication of two consensus statements recommending the 
formal application of PVTs in both forensic and clinical assessments (Bush et al., 
2005; Heilbronner et al., 2009). Nearly all neuropsychologists surveyed utilised both 
standalone and embedded validity measures and only 6% believed them to be 
‘optional or unnecessary’ in clinical assessments (Martin et al., 2015). It is 
134	
	
interesting to note the contrast in beliefs and practice between North American and 
European clinicians regarding the use of PVTs, whereby North American clinical 
practice appears to have greater convergence between research and clinical findings. 
It is possible that this reflects the increased emphasis on medicolegal and forensic 
work in North American neuropsychology and a longer tradition of performance 
validity testing (Suesse, Wong, Stamper, Carpenter, & Scott, 2015). 
   My experiences are consistent with the European data from the Dandachi-
Fitzgerald et al. (2013) study, as it would appear that, in day-to-day NHS clinical 
practice, clinicians may be more likely to rely on subjective judgement for the 
evaluation of performance validity than on psychometric tests. In line with this, the 
McCarter et al. (2009) survey of UK clinicians highlighted a prevailing belief that 
‘invalidity would be obvious’ in patient presentation or test scores. This view is 
somewhat problematic as there is ample evidence from across the social sciences to 
suggest that clinician impressions can be unreliable. For example, a meta-analytic 
review comparing clinical versus mechanical (that is, formal or statistical) decision-
making demonstrated the ‘general superiority’ of mechanical prediction across 
clinical settings: this effect held for both medical professionals and psychologists and 
for experienced and inexperienced clinicians (Grove, Zald, Lebow, Snitz & Nelson, 
2000). As regards the judgement of performance validity, it has been demonstrated 
that the use of heuristics as decisional simplification strategies can influence clinician 
assessment (Guilmette, 2013). The ‘representativeness’ heuristic, for example, 
describes the situation whereby the probability of an event is determined based on 
past experience or assumptions (Tversky & Kahneman, 1974), which may lead to the 
exclusion of actual base rate information in clinical decision-making. Given that base 
rate data on performance invalidity in NHS settings has been notable by its absence, 
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it is perhaps unsurprising that clinicians are more likely to resort to their own 
practice-based evidence to support judgements in this regard. It is hoped that the 
empirical study outlined in this thesis will supplement the evidence-base and that 
others will continue to research along this vein to assist clinician judgement using 
PVTs with their patient populations.       
    Further barriers to PVT use included practical considerations such as 
administration time and cost of measures (McCarter et al., 2009; Dandachi-
Fitzgerald et al., 2013). In addition, the McCarter et al. (2009) survey included 
concern amongst clinicians that PVTs are ‘unreliable’. Whilst the empirical study in 
this thesis certainly raises issues in this regard, it could also be asserted that ongoing 
reliance on subjective assessment alone is almost certainly incompatible with 
evidence-based practice (Dandachi-Fitzgerald et al., 2013). In line with this, I would 
query whether the lack of explicit guidance for clinicians regarding a) how to 
interpret PVTs with clinical populations and b) management strategies for 
individuals failing PVTs act as significant obstacles to implementation. These issues 
will be discussed in the remainder of this chapter.   
What are we actually testing when we use performance validity tests? What can test 
failure tell us? 
   A key narrative thread running through this thesis has been the importance 
of utilising PVTs as formal means of assessing the validity of neuropsychological 
data. The overarching message in professional guidelines is that to neglect this is to 
potentially “leave the door wide open to artificially supressed scores” (Green, 2003, 
p. 626). This perspective is based on the significant body of evidence focused on 
improving detection techniques, which has provided important information regarding 
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the validity of PVTs. Nonetheless, there remains a significant degree of tautology 
and confusion regarding the phenomenon in question when looking to apply the 
evidence-base outside of medicolegal or forensic practice. At a basic level, the 
nomenclature used within this field lacks clarity. My decision to utilise the term 
‘performance validity’ throughout this thesis was a conscious one, motivated by 
recent shifts in thinking away from more pejorative terminology using phrases such 
as ‘effort’, ‘negative response bias’ and particularly ‘malingering’ (see Larrabee, 
2012, for a discussion of this issue). In practice and in the literature these phrases are 
often used synonymously yet there are few accepted operationalised definitions of 
what the terms mean and how they might overlap or differ from each other. The very 
fact that they are used interchangeably and inconsistently is illustrative of the 
ambiguity which plagues this field. As a result of this, even after considerable time 
spent analysing and synthesising the literature, I am left with unanswered questions 
about how best to conceptualise diminished performance on PVTs and, in turn, what 
should be done with the information they add to clinical assessments.  
  PVTs were originally conceived in the 1980’s as malingering tests to be 
used primarily in the medicolegal arena. The literature has evolved, and there is now 
a general consensus that malingering is only one source of atypical performance on 
PVTs (McMillan et al., 2009; Merten & Merckelbach, 2013).  Scores below chance 
on these measures (for example, scoring under 25 on the 50-item Test of Memory 
Malingering [TOMM]; Tombaugh, 1996) continue to be accepted as indicative of 
malingering as this strongly suggests that the patient is voluntarily endorsing 
incorrect answers (Bush et al., 2005; Bigler, 2012). Cut-off scores on these measures 
are, however, are generally set significantly above chance levels, yet there is a 
tendency within the literature (and, in my anecdotal experience, within clinical 
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practice), to equate this ‘failed’ performance with commentaries regarding the degree 
of ‘effort’ applied by the examinee. The logic behind this is that PVTs are so 
straightforward that the only cognitive requirement needed to pass is a general level 
of engagement with the task (Bigler, 2014), but to what extent is this a useful 
heuristic for clinical practitioners? 
  Cognitive neuroscience research indicates that, aside from primary sensory 
stimulation, all other tasks require a degree of cognitive processing, no matter how 
simple the task may appear at a surface level (Bigler, 2014). This clearly creates an 
issue for proponents of PVT use, as it would make the task of teasing apart the 
organic from the non-organic symptomatology extremely challenging. Indeed, this 
issue was highlighted in both the systematic review and empirical paper, as it has 
been demonstrated that a) different forms of dementia with varying 
neuropathological bases differentially impact on PVTs tapping different cognitive 
processes and b) that people passing and failing PVTs do not appear to have globally 
suppressed scores on neuropsychological assessment. One the basis of these data, 
assuming assessment invalidity purely as a result of failed PVTs would not be 
empirically supportable as the scores could be picking up on features related to the 
organic basis of the individual’s condition.  
  PVT failure may also have a psychological basis beyond intentional 
underperformance. One school of thought is that diminished performance on testing 
may be part of a medically unexplained syndrome such as a somatoform disorder, 
and that non-conscious processes are acting to impact responding on PVTs. The 
‘non-conscious’ mechanisms are not well defined, but one suggestion is that anxiety 
may bias individuals to respond in a way which is congruent with their health beliefs 
(for example, that they are cognitively impaired as a result of a condition of the 
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brain; Kemp et al., 2008). Related to this, some authors have proposed that 
diminished PVT performance taps an aspect of illness behaviour (Bigler, 2014). It is 
pertinent to this discussion to consider the association between illness behaviour and 
the potential benefits that society provides to individuals assuming the sick role, 
particularly when the sickness is a result of a physical condition as opposed to 
psychological or emotional disorders (Bass & Halligan, 2014). The determinants of 
illness behaviour are complex and multifactorial, but it is not a necessary condition 
that this behaviour is underpinned by consciously mediated choice or intention to 
deceive as would be the case for a diagnosis of factitious disorder or malingering. 
Psychological frameworks are beginning to emerge which identify other pathways to 
a behavioural phenomenon which may present in a similar way. For example, 
Merckelbach and Merten (2012) propose a cognitive dissonance model whereby 
individuals may initially misreport symptoms, but to resolve the internal conflict 
evoked by this behaviour (for example where beliefs about their own honesty are 
challenged by their actions) they begin to ‘deceive’ themselves that fabricated 
experiences are genuinely felt. Such a perspective emphasises that there are no sharp 
demarcation lines between malingering, somatoform or medically unexplained 
symptoms as would be suggested by the DSM-V taxonomy, and that perhaps it 
would be more helpful to consider these issues along a continuum.  
   In examining this debate it is clear that there is no parsimonious account 
which would explain why people fail PVTs. Whilst Occam’s razor may favour 
“uncooperativeness” or similar (Merten & Mercklebach, 2013), this cannot be 
assumed to be the case for all patients and to draw this conclusion is to fail to take 
into account the myriad reasons which may underpin diminished scores. Given the 
evidence covered here, it would seem that neuropsychological test performance is 
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best considered as a construct: something that is not directly observable but can be 
explored using PVTs as a tool. If PVTs are considered in this way, perhaps this 
overcomes the seemingly insurmountable problem of whether or not they enable 
clinicians to impute motivation and volition, conscious or unconscious processes, 
organic or non-organic symptoms or internal or external goals (Berry & Nelson, 
2010). This is in line with the perspective offered by Rogers, Sewell and Gillard 
(2010), which echoes the idea that PVTs cannot claim to identify malingering (even 
if, like the TOMM, they purport to do so in their title), but rather can only aim to 
detect invalid symptoms “without any assumptions about…goals” (Rogers et al., 
2010, p. 5). Instead, low scores on PVTs may act as prompts for clinicians to think 
more broadly about how they conceptualise the individual and as one piece in a 
formulation jigsaw. As highlighted by Dandachi-Fitzgerald et al. (2013), scientific 
progress in this area feels limited to the improvement of detection techniques at the 
expense of exploring conceptual issues which “provide meaning to non-credible 
symptoms” (p. 782): perhaps future research needs to shift focus to shed light on the 
latter. 
What do we do with failed PVTs in clinical assessments? 
   Hand-in-hand with a lack of clarity regarding what PVTs can show us, 
there is a limited evidence base focusing on the management of patients thought to 
be displaying invalid performance. The BPS guidelines (McMillan et al., 2009) 
provide some practical recommendations for how to manage suspected ‘poor effort’ 
within the assessment session. These emphasise that clinicians should actively 
reconsider the planned assessment (for example, whether additional PVTs need to be 
incorporated) but to continue testing such that sufficient information is available to 
produce a general formulation. The TOMM manual (Tombaugh, 1996) offers 
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guidance regarding how to communicate test failures in reports to clinicians and 
patients. A much-cited paper by Carone, Iverson & Bush (2010) further tackles the 
issue of cognitive assessment feedback in the context of PVT failure, providing a 
comprehensive framework to support clinicians to discuss this issue transparently 
and therapeutically. This is pertinent given findings of the Dandachi-Fitzgerald et al. 
(2013) survey, where respondents were divided regarding how they communicated 
issues around performance validity to their patients.  
   Other authors have examined the impact of speaking openly with patients 
about invalid performance during testing. Suchy, Chelune, Franchow & Thorgusen 
(2012) found that after confrontation regarding ‘non-valid’ PVT performance, two 
thirds of patients in a non-forensic sample produced valid scores on subsequent re-
examination, both on the PVT and subsequent memory testing. This suggests that by 
tackling the issue directly in the assessment context, the clinician increases the 
likelihood of obtaining valid results and may gain additional insights regarding the 
cause of the failed PVT, which would likely help mitigate some of the issues raised 
in the previous section regarding our understanding of what PVT failure may 
represent. Alongside this, however, Carone et al. (2010) acknowledge that clinicians 
may experience ‘anticipatory fear’ in feeding back potentially contentious 
information about performance validity to clients, which again leads one to question 
if this is a barrier to the systematic use of PVTs in clinical settings.  
     Aside from management in vivo during testing and considerations 
regarding the communication of PVT results to clients and professionals, there is 
little written regarding psychological approaches for people who fail PVTs. Of note 
is that the TOMM manual emphasises the utility of “…trying to determine the 
motivation underlying the exaggerations and then including this information as part 
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of the final diagnosis, along with suggested interventions” (Tombaugh, 1996; p. 22). 
There is no guidance given, however, on what management strategies may be 
particularly useful for this cohort of patients. Again, this is potentially related to the 
origins of this literature in the medicolegal field, where PVTs perform a more binary 
function to help clinicians establish whether or not there are non-organic aspects of 
an individual’s presentation. Applying PVTs in the clinical setting where clinicians 
may continue to see the patient therapeutically beyond the assessment, however, 
requires a somewhat more nuanced view which follows in the tradition of 
collaborative, person-centred care. This is one which is based on sound formulation 
of the patient’s presentation which does not seek to mitigate the subjective 
experience of the patient by attributing symptoms directly to lack of ‘effort’ or 
motivation, but to provide a foundation for alternative explanations and therefore 
treatment approaches (Bass & Halligan, 2014). This perspective has been 
summarised succinctly by Stone & Boone (2007), who stress that reducing 
performance validity to ‘moral failing’, as inferred by some labels applied to describe 
this phenomenon (‘feigning’, ‘malingering’, ‘non-credible’ and so on), is unhelpful, 
and detracts the clinician from examining clues as to why the behaviour is occurring.  
Summary 
  This appraisal has covered three areas which, on completion of this project, 
I felt warranted further exploration. I began with a consideration of my experiences 
working in neuropsychology settings with clinicians, and reflected on the 
inconsistent application of PVTs in NHS clinical practice despite clear professional 
guidelines and a large evidence-base emphasising the utility of incorporating PVTs 
in neuropsychological assessments. Having further explored the lack of clarity 
around what PVTs can tell us about performance and the dearth of guidance 
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regarding how to manage and intervene with individuals failing PVTs, it is perhaps 
not surprising that clinicians elect not to incorporate these measures on a systematic 
basis. It would be helpful for future research to more fully address these issues and, 
as the evidence-base evolves, for this to be incorporated into clinical guidelines. The 
discipline of neuropsychology has a tradition of strong, scientifically-based practice 
which is an area of particular strength when compared to other specialities in 
healthcare (Schroeder et al., 2016). Given that the area of performance validity 
testing is receiving significant research attention at the current time, this is now a 
good opportunity to consider these emerging issues. I would agree with the position 
of Stone & Boone (2007) that performance validity is “fascinating…worthy of 
continued, collaborative and enthusiastic research” (p. 11), but that field now needs 
to evolve from understanding how we recognise performance invalidity towards 
understanding the behavioural phenomenon of ‘invalid performance’ in greater 
depth. By doing so, this represents an important therapeutic step to understanding our 
patients’ needs.  
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Description of joint projects 
The empirical study was conducted in part collaboration with a Salomons 
DClinPsy student, Jessica Hooker, whose thesis is due for completion in summer 
2018. The current study focused on performance validity test (PVT) pass and fail 
groups in terms of differences in cognitive testing. My colleague’s thesis will look to 
examine the results of symptom-validity tests (SVTs) in terms of group differences 
in self-reported affective and personality variables. SVT information is only 
available for the archival data (see Part 2, Method section), therefore only these data 
are shared between the projects. Both researchers completed separate applications for 
ethical and local research and development office approval. Completion of the 
archival database was done jointly. All analysis and write-up has been conducted 
separately. 
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